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ABSTRACT 
 
Social Stress Exacerbations on Acute Theiler’s Virus Infection: A Role for 
Interleukin-6.  (August 2006) 
Robin Ranee Johnson, B.A.S.A., University of Nebraska; 
B.S., Colorado State University; 
M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Mary W. Meagher 
 
Neurodegenerative diseases, such as multiple sclerosis (MS), are 
adversely affected by both stress and inflammation. Theiler’s murine 
encephalomyelitis virus infection is an excellent animal model of MS, allowing 
examination of central nervous system inflammation during the acute phase of 
infection.  Social disruption stress exacerbates acute Theiler’s virus infection.  
Both social disruption stress and Theiler’s virus infection elevate the pro-
inflammatory cytokine, Interleukin-6 (IL-6).  The current study examined the 
necessity and sufficiency of IL-6 in mediating the negative effects of social 
disruption stress in acute Theiler’s virus infection.  Experiment 1 blocked IL-6 
function with a neutralizing antibody administered simultaneously with social 
disruption stress.  All mice were then infected, and measures of illness, motor 
impairment and physiological signs of disease were collected up to 21 d post-
infection.  Experiment 2 administered exogenous IL-6 for one week (replacing 
social disruption with the cytokine treatment), followed by infection.   Measures 
  iv 
identical to those collected in Experiment 1 were collected for up to 21 d post-
infection.  Results indicate that IL-6 is necessary for the development of the 
sickness, motor impairment, and immunological effects of social stress in acute 
Theiler’s virus infection.  In contrast, IL-6 alone can induce some, but not all, of 
the sickness behavior exacerbations, and was not sufficient for the development 
of either motor impairment or immunological effects previously associated with 
social disruption stress.  These results have many important implications for 
further research in the effects of social stress on Theiler’s virus infection, as well 
as clinical implications for both MS and other inflammatory mediated diseases, 
such as Alzheimer’s disease and Parkinson’s disease.   
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NOMENCLATURE 
 
" Inch 
AbTx Antibody to IL-6 Treatment 
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°C Degrees Celsius 
CNS Central Nervous System 
CO2 Carbon Dioxide 
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mL Milliliter 
µM Micromole 
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mo Month 
N Newton 
NE Norepinephrine 
NF-κB Nuclear Factor- Kappa B 
ng Nanogram 
NIH National Institutes of Health 
NINDS National Institute of Neurological Disorders 
NON Non-stressed, or Infected Control 
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pi Post-infection 
pnd Post-natal Day 
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SAM axis Sympathetic-Adreno-Medullary Axis 
SDR Social Disruption Stress 
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Th or CD4+ T-helper Cells 
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TMEV Theiler's Murine Encephalomyelitis Virus 
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_______________ 
This dissertation follows the style of the Journal of Neuroimmunology. 
1. INTRODUCTION 
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s 
disease, and multiple sclerosis (MS) are a growing health concern.  Alzheimer’s 
disease is expected to increase in prevalence by 44% by 2050  (Alzheimer’s 
Association, 2005).  Parkinson’s disease prevalence will also increase as our 
population ages (NINDS, 2005b).  MS has increased in prevalence by 50% in 
women in the past 20 years, and is expected to continue on this trajectory 
(NINDS, 2005a).  These and other neurological disorders have at least two 
important factors in common.  First, stress has been associated with the onset 
and exacerbation of symptoms of all of these diseases (Ackerman et al., 1998; 
Ackerman et al., 2000; Backer, 2000; Mohr et al., 2000; Rabin, 2002; Rodriguez 
et al., 2003; Smith et al., 2002; Warren et al., 1982; Warren et al., 1991; Wilson 
et al., 2003).  Second, inflammatory processes contribute to the disease courses 
of all three of these neurodegenerative disorders (Matyszak, 1998; McGeer and 
McGeer, 1995).  Because of these similarities, examining the roles of stress and 
inflammation in one of these disease models may result in greater knowledge 
and understanding across many inflammatory-mediated neurodegenerative 
diseases. 
MS is a common inflammatory demyelinating condition of the central 
nervous system (CNS) (Oleszak et al., 2004).  Demyelinating lesions are 
associated with inflammatory cell infiltrates consisting of plasma cells
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(activated B-cells), macrophages/microglia, and T-cells.  The disease develops 
between the ages of 15 and 50 and results in the loss of motor, sensory, 
autonomic, and neurological function.  Most commonly, the disease manifests 
through loss of motor control or sensation in the limbs.  Other clinical signs 
include optic neuritis, sexual dysfunction, cognitive dysfunction, loss of bowel or 
bladder control, and neuropathic pain.  Although the etiology of MS is uncertain, 
research indicates that several environmental factors interact with genetic 
factors to cause disease (Kurtzke, 1993; Kurtzke and Hyllested, 1987; 
Noseworthy et al., 2000; Sospedra and Martin, 2005).  Potential environmental 
risk factors include, but are not limited to, viral infection and stress.  
Epidemiological studies suggest that exposure to viruses, such as Herpesvirus-6 
and Epstein Barr virus, in adolescence is associated with later, adult, 
development of MS (Acheson, 1977; Ascherio et al., 2001; Kurtzke, 1993; 
Sospedra and Martin, 2005).  While infection with these or other viruses may be 
necessary, it is not sufficient, as additional work has shown that the majority of 
the general population has antibodies to these viruses, and yet do not develop 
MS (Hernan et al., 2001).  Therefore, stress may be an important co-factor that 
interacts with viral infection to determine the development of MS.   
That stress, a psychological process, could have such potent effects on 
immunological processes is no longer controversial.  Seyle’s original theory of 
stress, the general adaptation syndrome, included a triad of immunologically 
significant consequences.  These included atrophy of the thymus and spleen, 
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primary immune organs, and enlarged adrenal glands (Selye, 1946).  Research 
over the past few decades has demonstrated that many mechanisms for cross-
talk are in place between the immune and stress systems.  Stress activates two 
primary physiological axes, the hypothalamic-pituitary-adrenal axis (HPA-axis) 
and the sympathetic-adrenal medullary axis (SAM-axis).  HPA-axis activation 
results in the release glucocorticoids (GCs) from the adrenal gland cortex.  In 
addition, the SAM-axis releases norepinephrine from sympathetic neurons, and 
both norepinephrine and epinephrine from the medulla of the adrenal glands.  
Virtually every immunological organ and all immune cells types have receptors 
for one or more of these products (McEwen et al., 1997).   
HPA-axis activation occurs when the paraventricular nucleus of the 
hypothalamus is stimulated, resulting in the release of corticotrophin releasing 
factor (CRF, also commonly referred to as corticotrophin releasing hormone or 
CRH), onto the pituitary gland.  The pituitary gland then releases 
adrenocorticotropic hormone (ACTH), which travels through the blood stream to 
the adrenal gland.  The adrenal gland cortex is then stimulated to release GCs.  
In humans the main GC is cortisol, while in rodents it is corticosterone.  The 
hypothalamus is originally stimulated differently, based on the type of stressor.  
If the stressor is systemic or physical, such as hemorrhage or surgery, the 
central nucleus of the amygdala is activated (Dayas et al., 2001; Herman and 
Cullinan, 1997).  In contrast, psychological or processive stressors, such as 
noise or restraint activate the medial nucleus of the amygdala, the bed nucleus  
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of the stria terminalis, and the preoptic area (Dayas et al., 2001; Herman and 
Cullinan, 1997).  The “pre-hypothalamic” activation areas for social stressors 
have not been investigated, and are unknown at this time.  These pathways are 
depicted in Fig 1.1.   
Simultaneous to HPA-axis activation, the SAM-axis is also triggered.  
Among other possible neural circuits, CRF projections from the hypothalamus 
lead to the locus coeruleus resulting in the activation of sympathetic neurons.  
The sympathetic neurons directly release norepinephrine, and the innervation of 
the medulla of the adrenal glands results in the release of primarily epinephrine, 
but also lesser amounts of norepinephrine into the blood.  SAM-axis can have 
faster action because norepinephrine is released through this direct neuronal 
activation as well as through hormonal activation of the adrenal medulla.  Since 
HPA-axis release of GCs requires hormonal activity, the SAM-axis action is 
usually detectable more quickly than HPA-axis action.  
The SAM-axis appears to act mainly through norepinephrine to alter 
immune function, either by directly innervating immune tissue or through 
receptors on immune cells.  Sympathetic innervation occurs throughout 
lymphoid tissue, including the lymph glands, thymus, spleen and bone marrow 
(Felten et al., 1998).  Norepinephrine can also influence the development and 
function of T-cells, and T-cell responses.  When naïve CD4+, or T-helper cells 
are exposed to norepinephrine, they are more likely to become Th-1 cells (these 
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helper T-cells aid cytolytic T-cell activity) (Madden et al., 1995).  However, 
norepinephrine is also more likely to recruit and aid in the function of Th-2 cells 
(these helper T-cells aid in B-cell activity) (Ramer-Quinn et al., 1997).  Thus, 
norepinephrine has divergent effects on T-cell function, depending upon when in 
the immune response it becomes part of the milieu.   
The HPA-axis affects the immune system through both CRF and GC.  
Inflammatory cells (such as macrophages and mast cells) have CRH receptors 
(Webster et al., 2002; Webster et al., 1998).  GCs act primarily through cellular 
receptors.  There are 2 subtypes of receptors, the mineralocorticoid (type 1) and 
the GC (type 2).  While the type 1 receptors have a higher affinity for 
endogenous GCs, immune cells, including monocytes and lymphocytes express 
mainly type 2 (GC) receptors.  Monocytes (macrophages, microglia) have the 
highest concentration, overall, followed by lymphocytes (B-cells, T-cells), while 
neutrophils have the lowest concentration (McEwen et al., 1997).  It should be 
noted that while this overall pattern has been verified, individual cells within a 
subtype population vary greatly in the concentration of receptors.  When GCs 
bind to a receptor in an immune cell, they act through the NF-κB transcription 
factor to decrease inflammatory gene transcription (Adcock et al., 2004).  NF-κB 
mediated transcription occurs for a broad range of cellular functions.  However, 
GCs only appear to alter gene transcription for cytokine production.  How this 
specificity occurs considering the commonality of NF-κB transcription in multiple 
cellular functions is unknown at this time.  The end result of GC action in 
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immune cells is to switch off the production of pro-inflammatory cytokines (IL-1, 
IL-6, and TNF-α), while simultaneously turning on production of anti-
inflammatory cytokine (IL-4, IL-10).  This appears to be the primary mechanism 
through which GCs are immunosuppressive (Adcock et al., 2004). 
The communication between the immune system and the stress systems 
is bidirectional (Watkins et al., 1995b).  The immune system can alter both of the 
stress axes as well.  The pro-inflammatory cytokine, IL-1β can bind to receptors 
in the hippocampus and act to turn off the HPA-axis, acting as part of the 
negative feedback loop that normally regulates HPA-axis activation (Watkins et 
al., 1995b).  In addition, peripheral IL-1β or TNF-α can bind to the vagus nerve 
and cause the release of IL-1β or TNF-α centrally (Fleshner et al., 1995; Goehler 
et al., 1997; Maier et al., 1998; Watkins et al., 1995a; Watkins et al., 1995b).  
Therefore, cytokine activity in the periphery can have concurrent effects 
centrally, inducing cytokine sickness behavior syndrome (Dantzer, 2001; 
Fleshner et al., 1998).  Cytokine sickness behaviors include body temperature 
changes, anorexia, weight loss, decreased motor activity, mechanical 
hypersensitivity, and anhedonia- a loss of interest in pleasurable activities.  
(Dantzer, 2001; Watkins and Maier, 2000).  These measures are known to be 
altered by IL-1β (Fleshner et al., 1995; Rachal Pugh et al., 2001), as well as 
TNF-α (Fleshner et al., 1995; Goehler et al., 1997; Maier et al., 1998; Watkins et 
al., 1995a; Watkins et al., 1995b).  Finally, activated CD4+ (T-helper) cells can 
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cause the release of norepinephrine from sympathetic neurons (Kohm et al., 
2000). 
The pro-inflammatory cytokine, IL-6 has a particularly interesting role in 
the bidirectional communication between the immune and stress systems.  
Various stressors are able to increase plasma IL-6, in the absence of any 
immunogenic compound, such as LPS (LeMay et al., 1990; Maes, 2001; 
Shizuya et al., 1998; Steptoe et al., 2001; Takaki et al., 1994; Zhou et al., 1996).  
IL-6 may also be produced by non-immunogenic tissue, including both neuronal 
and adipose tissue (Murphy et al., 1999; Papanicolaou and Vgontzas, 2000).  All 
cytokines act primarily in a paracrine manner, but IL-6 also has many endocrine-
like actions (Papanicolaou and Vgontzas, 2000).  Interestingly, IL-6 can, in 
contrast to IL-1, activate the HPA-axis (independent of CRF), during either an 
immune or stress response (Bethin et al., 2000).  IL-6 can also induce some of 
the cytokines sickness behaviors (fever and increased mechanical sensitivity).  
However, more significant effects on sickness behavior occur through IL-6 
synergism with IL-1β and TNF-α, allowing these cytokines to develop more 
significant levels of sickness behavior (Bluthe et al., 2000; Bluthe et al., 1994). 
Based on the known interactions between the immune and stress 
systems, the previously stated hypothesis that stress may interact with exposure 
to viruses to increase the likelihood of the development of MS becomes more 
viable.  Evidence for this theory exists in both human and animal work.  In 
humans, elevated periods of conflict and disruption of routine are associated 
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with increased MS lesion development, and stress often precedes initial 
symptom diagnosis onset in MS, as well as further exacerbations of symptoms 
(Mohr et al., 2000; Mohr et al., 2004; Mohr and Pelletier, 2005).   Animal models 
of MS have also found that stress exacerbates the disease course.  Previous 
work from our laboratory has demonstrated the restraint stress exacerbates the 
early, acute phase of Theiler’s virus infection (Campbell et al., 2001; Mi et al., 
2004; Sieve et al., 2004), and these exacerbations can lead to more severe 
chronic phase (the MS-like phase) as well (Sieve et al., 2004).  Acute stress also 
exacerbates another animal model of MS, experimental allergic 
encephalomyelitis (EAE) (Chandler et al., 2002).  
Theiler's virus infection (TMEV) is a biphasic disease that causes an 
acute CNS inflammatory phase followed by a chronic neuroinflammatory/ 
autoimmune demyelination phase similar to MS in mice.  The chronic phase of 
the disease has many similarities, both behaviorally and physiologically with the 
chronic progressive type of MS (Lipton, 1975; Oleszak et al., 2004).   Previous 
work from our laboratory has found that social disruption stress (SDR) prior to 
infection with Theiler’s virus infection leads to a more severe disease course 
(Johnson et al., in submission; Johnson et al., 2004).  Given that preceding 
periods of stress negatively impact both MS and Theiler’s virus infection, 
Theiler’s virus appears to provide an important model to examine this issue in 
MS.  In addition, acute Theiler’s virus infection is highly inflammatory within the 
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CNS, adding relevance to any findings not only for MS, but the other 
inflammatory mediated neurodegenerative diseases (e.g. Alzheimer’s disease). 
Past studies have demonstrated that the social stressor, social disruption 
(SDR) alters the disease process of both acute and chronic TMEV infection in 
several ways when SDR was applied prior to infection.  In the acute phase, SDR 
resulted in greater motor impairment, induced GC resistance (GCR), elevated 
CNS inflammation, and altered viral clearance compared to non-stressed 
animals (Johnson et al., 2004).  Failure to clear the virus in the acute phase is 
necessary (although not sufficient) for the development of the chronic, 
demyelinating phase.  In the chronic phase, SDR was associated with early 
onset of chronic phase motoric impairment, elevated antibodies to TMEV and 
elevated auto-antibody development to myelin proteins (Johnson et al., in 
submission).  Finally, previous studies our laboratory have found that the 
severity of the acute phase is highly correlated with both the time of onset and 
the severity of the chronic phase (Johnson et al., in submission).  These results 
occurred when SDR was applied prior to infection.  When SDR is applied 
concurrent with infection, disease severity in both the acute and chronic phase 
of TMEV was alleviated compared to non-stressed animals.  Taken together, 
these studies indicate that interventions that reduce the severity of the acute 
phase are likely to have positive effects for the chronic MS-like phase. 
IL-6 may be an important molecule mediating or moderating the effects of 
SDR in acute TMEV infection.  In humans, psychological stressors such as 
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examination stress, the Stroop color-word conflict task, and mirror tracing all 
significantly elevate IL-6 in circulation (Maes, 2001; Steptoe et al., 2001).   In 
addition, caretakers for Alzheimer’s patient’s have elevations in IL-6 levels that 
do not dissipate even once care giving is terminated (Kiecolt-Glaser et al., 
2003).  A broad range of stressors also induce IL-6 in animals including foot 
shock, restraint, and immobilization (LeMay et al., 1990; Shizuya et al., 1998; 
Takaki et al., 1994; Zhou et al., 1993).  Recently, social stressors have been 
shown to be powerful stimuli for inducing pro-inflammatory cytokines (Gaab et 
al., 2005; Merlot et al., 2003; Merlot et al., 2004; Stark et al., 2002; von Kanel et 
al., 2005; von Kanel et al., 2006).  When rats went from individual housing to 
didactic pairings, IL-1β became elevated, particularly in the dominant animal 
within each pair (Fano et al., 2001).  SDR is also associated with elevated IL-6 
and TNF-α in circulation (Avitsur et al., 2005; Stark et al., 2002).  In addition, 
SDR causes lippopolysaccharide (LPS)-stimulated spleen cells to release 
greater levels of IL-1β, IL-6, and TNF- α (Avitsur et al., 2002).  The ability of 
LPS-stimulated cells to release increased levels of pro-inflammatory cytokines is 
not altered by the introduction of increasing concentrations of glucocorticoids 
(Avitsur et al., 2002).   
Although the immune and stress systems have many mechanisms for co-
regulation, this regulation can fail.  The failure of corticosteroids to regulate 
immune function is referred to as GCR.  As noted previously, GCs are normally 
immunosuppressive, primarily by suppressing pro-inflammatory production and 
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inducing anti-inflammatory cytokine production.  In GCR, the GCs fail to down-
regulate immune function.  This dysregulation can manifest through multiple 
functional outcomes.  For example, in parental caregivers of pediatric cancer 
patients, serum IL-6 levels do not decrease with exposure to the synthetic GC, 
dexamethasone (Miller et al., 2002), indicating that IL-6 regulation is no longer 
under the control of GC.  Additionally, depressed patients often have elevated 
corticosteroid levels concurrent with elevated pro-inflammatory cytokines, and 
GCR may be an important in the relationship between depression and cytokine-
sickness behavior.  In recent years, rodent models of social stress consistently 
induce GCR.  Paired fighting, social defeat, and social disruption all induce GCR 
in the splenic macrophages (Avitsur et al., 2001; Bailey et al., 2004; Stark et al., 
2001).  GCR appears to develop exclusively in social stress animal models, with 
other types of stress (e.g. restraint) failing to induce this phenomena (Avitsur et 
al., 2001).  Interestingly, pro-inflammatory cytokines can increase the expression 
of the beta subtype of the GC receptor, which has been associated with the 
development of glucocorticoid resistance (Necela and Cidlowski, 2004).  Thus, 
elevated proinflammatory cytokines may be related to the development of GCR, 
while GCR also results in the production of elevated proinflammatory cytokines. 
In the SDR model, GCR develops in a well-characterized manner.  Social 
stress activation of the HPA-axis and the SAM-axis leads to the trafficking of 
GC-insensitive macrophages from the source bone marrow to the spleen (Engler 
et al., 2005).  This subtype of macrophage is normally present within the 
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organism, but does not typically leave the bone marrow.  Because bone marrow 
is innervated with noradrenergic neurons, norepinephrine may be an important 
signal for the altered trafficking pattern of macrophages; however this is 
unknown at this time.  Over time (at least four nights of SDR), the GC insensitive 
macrophages become the dominant cell type in the spleen (Avitsur et al., 2002).  
Normal splenic macrophages, when stimulated with LPS, will survive at higher 
rates than non-stimulated macrophages.  If the LPS stimulated cells are then 
exposed to increasing concentrations of corticosteroid, cell proliferation is 
reduced in a dose dependent manner.  The GCR macrophages maintain the 
LPS alone levels of proliferation when exposed to increasing levels of 
corticosteroids.  The failure of corticosteroid to reduce cell proliferation occurs 
because the macrophages no longer react to the corticosteroid’s regulation.  The 
regulation is no longer effective because while the GCR macrophages have 
normal GC receptors, the receptor-GC bound complex does not translocate into 
the nucleus.  Because the bound complex does not translocate, the NF-κB 
transcription pathway is not induced, and the GCs have no regulatory power 
(Quan et al., 2003).   
Macrophages are an important source of pro-inflammatory cytokines (IL-
1, IL-6, TNF-α) during both innate and acquire immune responses.  These 
cytokines recruit and signal other cells (including other macrophages, microglia, 
etc.) to the site of infection, and stimulate surrounding monocytes to proliferate.  
In the CNS, microglia (the native CNS monocyte and immune cell) become 
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activated, allowing them to become antigen presenting cells, furthering the 
persistence of the inflammatory-immune response (Mack et al., 2003).  Receptor 
bound GCs that translocate to the nucleus of macrophages act to switch the 
production away from proinflammatory cytokines to anti-inflammatory cytokines.  
The anti-inflammatory cytokines signal the other area macrophages to stop 
proliferating and signal other cells to stop migrating to that area.  Thus, GCR 
macrophages will not switch “off”, and production of proinflammatory cytokines 
continues.  In previous SDR-TMEV studies, inflammation was exacerbated by 
social stress, possibly through GCR related dysregulation of the macrophages 
and microglia.  The relationship of social stress to inflammation becomes highly 
relevant in light of the aforementioned inflammation-neurodegeneration and 
neurodegeneration-stress interactions in neurodegenerative diseases, including 
MS.   
Our laboratory has previously demonstrated that SDR applied prior to 
infection lead to exacerbated motor impairment in both the acute and chronic 
phase of TMEV (Johnson et al., in submission; Johnson et al., 2004).  In 
addition, SDR applied prior to infection also inhibited viral clearance and 
elevated inflammation in the acute phase (Johnson et al., 2004).  The current 
studies examine the role of IL-6 in the acute phase effects of SDR applied prior 
to infection.  Others have shown that both IL-6 and TNF- α are elevated by SDR 
(Avitsur et al., 2005; Stark et al., 2002).  Our laboratory has also shown that IL-6 
is slightly elevated at day 9 post-infection (pi) in circulation (Johnson et al., in 
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submission), while previous attempts to examine TNF-α by our laboratory have 
failed to find any changes in this cytokine due to either SDR and/or infection.  
TMEV infection is also associated with elevated IL-6.  IL-6 is an essential signal 
allowing microglia to activate and become competent antigen presenting cells in 
TMEV infection (Mack et al., 2003; Olson et al., 2001; Palma et al., 2003).  IL-6 
production is also elevated in brain tissue as a whole and in cultured astrocytes 
from TMEV infected mice (Rubio and Sierra, 1993).   
The objective of Experiment 1 was to determine the necessity of IL-6 by 
blocking IL-6 with a neutralizing antibody and then replicating our previous acute 
phase experiments.  Others have used this technique to block IL-1, IL-6, and 
TNF-α in both rats and mice (Herx et al., 2000; Jean Harry et al., 2003; 
Laflamme et al., 1999; Lebel et al., 2000).  We hypothesized that by blocking IL-
6, we would block the negative effects of SDR.  In the current study, mice were 
cannulated and given daily intracerebral ventricular cannula injections of the 
neutralizing antibody to IL-6 several hours prior to administration of our typical 
SDR protocol.  Following the SDR/antibody administration, animals were 
infected and examined for the development of sickness behaviors (anhedonia, 
reduced activity, reduced body weight, hyperalgesia) and motor impairment 
(hind limb impairment score, activity, vertical activity, sensitivity to physical 
stimuli, and stride length).  In order to compare immunological outcomes with 
our previous work, viral clearance and inflammation in both brains and spinal 
cords was examined in separate subsets of mice.   
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The objective of Experiment 2 was to examine the sufficiency of IL-6 in 
replicating the effects of SDR, by administering exogenous IL-6 instead of SDR.  
We hypothesized that replacing SDR with IL-6 would fail to replicate the effects 
of SDR, as IL-6 is only one of many inter-related factors that may be responsible 
for the negative effects of SDR.  Once again, the sickness, motor impairment, 
and immunological measures taken similar to Experiment 1 were collected to 
allow comparison and consistency across both the current and previous studies 
using SDR applied prior to TMEV infection.    
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2. GENERAL METHODS 
2.1.  Animals 
Male Balb/cJ mice were acquired from Jackson Labs (Bar Harbor, ME).  
Mice arrived from the breeder at post-natal day (pnd) 23 and were weighed and 
assigned to individual cages.  On pnd 24 mice were cannulated (see below).  
Following cannulation, mice continued to be individually housed for 48 h.  On 
pnd 26, mice were placed in group-housing, 3/cage, counterbalanced by weight.  
Mice were maintained on a 12-h light/dark cycle (0500-h/ 1700-h) with ad libitum 
access to food and water, with the exception of the 2-h SDR sessions.   
Intruders for the SDR were retired male breeders, 6-to-8 mo of age, 
housed with sterilized females to increase territoriality and aggressive behavior.  
The intruders were selected based on latency to attack both peers and 
adolescents.  All intruders consistently attacked peers within 30 s and 
adolescents within 2 min on 3 separate occasions.  All animal care protocols 
were in accordance with NIH Guidelines for Care and Use of Laboratory Animals 
and were approved by the Texas A&M University Laboratory Animal Care and 
Use Committee (ULACC). 
2.2.  Cannulation surgery 
Mice were anesthetized with isoflurane gas (2-5%), heads shaved, eyes 
coated with petroleum jelly, and placed in a mouse adapted stereotaxic device 
(fitted with a mouse nose cone (#51625, #51609, Stoelting, Wood Dale, IL).  The 
isoflurane delivery system was purchased from Vet Equip (#901806, 
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Pleasanton, CA), and the gas recovery system was purchased from Surgivet 
(model AES, Waukesha, WI).   An incision was made longitudinally along the 
midline of the skull and the skull was exposed (hemostats were not needed).  
The periosteum was removed with a sterile cotton swab, and 2% lidocaine was 
applied to the wound.  Bregma was located and noted.  Rostral-caudal leveling 
was accomplished by measuring the vertical position (z plane) of lambda and 
bregma and ensuring that they were equalized.  The skull was swabbed dry, and 
the cannulation hole was drilled at +1 mm lateral to bregma and -.4 mm rostral 
to bregma over the left lateral ventricle (based on Paxinos & Franklin).  Guide 
cannula (33g) purchased from Plastics One (Roanoke, VA, C315GS-2/SPC), 
were pre-cut to a depth of 1.75 mm, and implanted and secured with 
cyanoacrylic gel according the manufacturer’s suggestion.  Mice were then 
wrapped with bubble wrap to aid in insulation to combat hypothermia induced by 
anesthesia, and placed back in the home cage that was warmed over a heating 
pad.  Mice were monitored until fully awake and ambulatory.  Once ambulatory, 
bubble wrap was removed, and mice were returned to the animal colony.  For 
pain control post-surgery, mice were provided with water treated with Tylenol 
(325 mg/ 2000 mL).  To aid in recovery mice were also provided with food 
softened with the Tylenol treated water in the cage.  Mice were allowed to 
recover approximately 6 d prior to any further procedures.   
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2.3.  Social disruption (SDR) stress   
For the stressed mice, intruders were introduced into the cage of resident 
mice at dark cycle onset (1700 h) for a period of 2 h for a total of 6 SDR 
sessions the week prior to infection, beginning on pnd 30.  SDR occurred for 3 
consecutive sessions, then 1 night off, followed by 3 additional consecutive 
sessions (Avitsur et al., 2001; Stark et al., 2001), in a separate procedure room.  
Control mice (NON) remained in the colony room, undisturbed for the duration of 
SDR.  SDR sessions were monitored to ensure that the intruder attacked the 
residents and that the residents demonstrated submissive behaviors.  Intruders 
that did not attack within 10 min of session initiation were replaced, and the 
session continued for the remaining 2 h.   
2.4.  Virus and infection 
 The BeAn strain of Theiler's virus (obtained from Dr.  H.L.  Lipton, 
Department of Neurology, Northwestern University, Chicago, IL.) was 
propagated and amplified in L- cells.  The culture supernatant containing 
infectious virus was aliquoted, titrated and stored at –80º C before use (Welsh et 
al., 1987).  Mice were anesthetized on day 0 pi/ pnd 37 with isoflurane (Vedco 
Inc., St. Joseph, MO) and injected intracranially (ic) with a 27-g needle into the 
right mid-parietal cortex (depth approximately 1.5 mm) with 5 x 104 pfu of the 
BeAn strain of Theiler’s virus in a 20-µl volume as previously described 
(Campbell et al., 2001; McGavern et al., 1999; McGavern et al., 2000; Rose et 
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al., 1998; Theil et al., 2000).  Inoculation for all subjects occurred at 2100 h, 
following the last SDR session. 
2.5.  Illness measures 
CNS inflammation is associated with a range of sickness 
behaviors/measures, very similar to cytokine-induced sickness syndrome.  
These include body temperature changes, anorexia, weight loss, decreased 
motor activity, mechanical hypersensitivity, and anhedonia- a loss of interest in 
pleasurable activities (Barak et al., 2002a; Barak et al., 2002b; Dantzer, 2001; 
Pollak et al., 2000; Pollak et al., 2003a; Pollak et al., 2003b; Watkins et al., 
1995b).  These responses are associated with the secretion of both peripheral 
and central proinflammatory cytokines.   
2.5.1. Body temperature 
Body temperature changes are common with acute phase responses due 
to infection.  In contrast to other mammals, mice commonly develop hypothermia 
during at least the first 24 h of an immune response.  Body temperature can be 
expected to decrease by .5 - 4 °C pi under normal circumstances (Dybing et al., 
2000; Leon, 2002; Leon et al., 1998; Wang et al., 1997).  Body temperature was 
measured daily at 0900-h, beginning the morning prior to infection for baseline, 
and continuing through day 7 pi.  Body temperature was measured using a laser 
temperature gun (Ex-Tech 47257), set to Celsius and sensitive to .1°C.  Each 
mouse was scruffed, and the laser guide was aimed at the abdomen, and the 
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temperature indicated on the gun was recorded.  Each mouse was tested three 
times each morning, and the average analyzed.   
2.5.2. Sucrose preference   
Sucrose preference was used to assess anhedonia from day -1 pi 
through day 7 pi.  Mice were provided with a 2% sucrose solution and plain tap 
water beginning at day -11 pi in identical 500 mL water bottles.  Assessment of 
preference began at day -7 pi, by weighing each bottle to determine intake from 
each bottle every 24 h, at 0900-h.  Preference was determined by comparing 
sucrose water intake to total fluid intake (g of sucrose/ (g of sucrose + g of tap 
water).  Preference was acquired when 60% or more of fluid intake was sucrose 
water.  Only cages that met criteria prior to infection were included in analysis.  
2.5.3. Weight loss  
  Sickness behavior related weight loss was assessed from days -1 
through 1 pi (Experiment 1), or days -1 through 7 pi (Experiment 2) .  Each 
mouse was weighed using a scale sensitive to .01 g, each morning at 0900-h.   
2.5.4. Motor activity   
To assess sickness behavior related activity decreases, open field 
horizontal activity at day 1 pi was measured.  The apparatus consisted of six 
optical beam activity monitors (Model RXYZCM-16), equipped with two banks of 
eight photocells on each wall, were used to measure locomotion activity, and 
The system utilizes a multiplexer-analyzer and Versamax software (Model DCM-
4, Omnitech  Electronics, Columbus, OH), used to measure locomotion activity, 
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located in an adjacent room.  White noise (64 dB) was continually present to 
mask extraneous disturbances.  Each box was modified for use with mice by 
placing a bench paper liner under a false Plexiglas floor, and using 2 Plexiglas 
dividers that separated the larger device into four equal sized, smaller 
chambers.  These adaptations allowed two mice to be placed in each larger 
chamber for each session, one in the lower left chamber, and another in the 
upper right chamber.   Mice were habituated in the chambers for 1-h, on pnd 28, 
prior to baseline measure collection at 1500-h.  Baseline assessment occurred 
on pnd 29.  All testing was conducted in the dark beginning at 1500-h, for 30 
min.  The baseline level for each animal was subtracted from the day 1 pi levels 
for assessment, to control for any individual differences across animals.  
2.5.5. Mechanical sensitivity   
Mice were habituated to the sensitivity apparatus for 20 min prior to 
assessment.  The apparatus consisted of a 2 mm gauge screen placed 4”-to-6” 
from a countertop.  Each screen was large enough to accommodate 2-to-3 mice.  
Each mouse was placed under a one pint sized Rubbermaid container during 
habituation and testing.  Multiple screens were set up each session to 
accommodate running six mice at a time.  After the 20 min habituation period, 
von Frey filaments (Stoelting) were applied to the pad of each hind limb starting 
with the smallest filament.  Each filament was applied to the left, then right, then 
right, then left hid paw in an ABBA manner.  Each filament was tested on each 
mouse prior to continuing with successive sized filaments (ascending).  Each 
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mouse was tested until the first withdrawal response occurred, and the size of 
that filament was recorded.  For the second trial, the order of filaments was 
reversed (descending), and the last filament to elicit a withdrawal response was 
recorded.  Each mouse was tested for three trials, ascending, descending, and 
then the third trial is ascending again.  For sickness related mechanical 
hypersensitivity, mice were tested at day 1 pi, and greater sensitivity was 
expected.  
2.6.  Behavioral assessment of motoric impairment   
Multiple measures of psychomotor behavior were examined.  These 
included: hind limb impairment ratings, locomotor activity (in the vertical and 
horizontal planes), mechanical sensitivity, and footprint stride length.   
2.6.1. Hind limb impairment (HLI)  
Mice were assessed for hind limb impairment beginning at day -1 pi and 
continuing through days 7 or 21 pi, as appropriate.  The hind limb impairment 
scale has been presented elsewhere (Johnson et al., 2004).  A rater blind to the 
subject’s experimental conditions assessed hind limb impairment.  All subjects 
underwent the exact same scoring procedure independent of symptoms or 
experimental condition.  Individual mice were placed on a floor grid, with 1 mm 
wide bars running in parallel every 10 mm.  The mice were inverted on the grid, 
so that they were hanging upside-down.  The rater then assessed hind limb 
weakness or paralysis.  A separate numeric score was given for each hind limb, 
based on the symptoms of impairment the mice display (0=healthy; 1=slight 
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weakness in grip; 2=clear weakness in grip; 3=slight paralysis; 4=moderate 
paralysis, 5=complete paralysis with muscle tone, 6= complete paralysis with no 
muscle tone (Johnson et al., 2004).  These separate scores were then added 
together and the combined score analyzed. 
2.6.2. Open field activity monitoring   
Motor impairment related activity decreases, open field horizontal and 
vertical activity, were collected on days 4,7,11, and 18 pi.  The apparatus 
consisted of six optical beam activity monitors (Model RXYZCM-16), equipped 
with two banks of eight photocells on each wall, were used to measure 
locomotion activity, and The system utilizes a multiplexer-analyzer and 
Versamax software (Model DCM-4, Omnitech  Electronics, Columbus, OH), 
used to measure locomotion activity, located in an adjacent room.  White noise 
(64 dB) was continually present to mask extraneous disturbances.  Each box 
was modified for use with mice by placing a bench paper liner under a false 
Plexiglas floor, and using 2 Plexiglas dividers that separated the larger device 
into four equal sized, smaller chambers.  These adaptations allowed two mice to 
be placed in each larger chamber for each session, one in the lower left 
chamber, and another in the upper right chamber.   Mice were habituated in the 
chambers for 1-h, on pnd 28, prior to baseline measure collection at 1500-h.  
Baseline assessment occurred on pnd 29.  All testing was conducted in the dark 
beginning at 1500-h, for 30 min.   The baseline level for each animal was 
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subtracted from each day pi levels for analysis, to control for any individual 
differences across animals.  
2.6.3. Mechanical sensitivity 
Mice were habituated to the sensitivity apparatus for 20 min prior to 
assessment every day of assessment (days 1, 7, 14, 21 pi).  The apparatus 
consisted of a 2 mm gauge screen placed 4”-to-6” from a countertop.  Each 
screen was large enough to accommodate 2-to-3 mice.  Each mouse was 
placed under a one pint sized Rubbermaid container during habituation and 
testing.  Multiple screens were set up each session to accommodate running six 
mice at a time.  After the 20 min habituation period, von Frey filaments 
(Stoelting) were applied to the pad of each hind limb starting with the smallest 
filament.  Each filament was applied to the left, then right, then right, then left hid 
paw in an ABBA manner.  The filament was tested on each mouse prior to 
continuing with successively larger sized filaments (ascending).  Each mouse 
was tested until the first withdrawal response occurred, and the size of that 
filament was recorded.  For the second trial, the order of filaments was reversed 
(descending), and the last filament to elicit a withdrawal response was recorded.  
Each mouse was tested for three trials, ascending, descending, and then the 
third trial is ascending again.  For motor impairment, mice were expected to 
require stimulation with larger filaments in order to elicit a response.  
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2.6.4. Stride length   
Footprint stride length and spread were assessed using a method similar 
to that used by McGavern et al. (1999, 2000) at day 20 pi.  This time point has 
previously been shown to be sensitive to the effects of SDR in the acute phase 
of TMEV infection (Johnson et al., 2006; Johnson et al., 2004).  Briefly, hind 
limbs were painted with blue paint while forelimbs were painted with red paint.  
Mice were then allowed to walk down a 2.5” by 36” runway lined with paper to 
record limb placement.  Mice were then cleaned thoroughly using a soft bristled 
paint brush and a mild soap and water solution, and dried.  Once the paint dried 
on paper strips, the stride length was measured in mm, for the first six steps.  
This has been shown to provide a reliable and valid measure of virally-mediated 
nerve damage and demyelination (McGavern et al., 1999; McGavern et al., 
2000).  
2.7.  Sacrifice 
Mice were sacrificed at either day 7 or 21 pi, for either histology or viral 
titer assay.  Each mouse was overdosed with ketamine (100mg/kg)/xylazine (5 
mg/kg), and bled from the brachial artery.  For histology, mice were perfused 
with 10 mL of PBS followed by 10 mL of 10% formalin.  For viral titer assay, 
mice were perfused only with PBS.  Spleen, thymus, brain and spinal cord were 
harvested appropriately and weighed.  For histology brains and spinal cords 
were placed in 10% formalin overnight, and sectioned as in previous studies 
(Johnson et al., 2004).  For the mice that were used for viral titer assays, 
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spleens were used for the corticosteroid sensitivity assay to assess GCR.  
Brains and spinal cords were flash frozen in liquid nitrogen, and stored at -80 ºC 
until viral titer assay was preformed.  
2.8.  Corticosteroid sensitivity assay 
On the sacrifice day, spleens were harvested to determine sensitivity of 
splenocytes to GC regulation (as per Stark, et al., 2001).  Briefly, spleens were 
placed in ice-cold Hank’s balanced salt solution (HBSS), and mashed to obtain a 
single cell solution.  Red blood cells were then lysed (red blood cell lysis, Sigma, 
St. Louis, MO), followed by a wash of HBSS+ 10% heat inactivated fetal bovine 
serum (FBS-HI, Equitech, Kerrville, TX).  Viable cells were then counted using 
trypan blue dye exclusion and re-suspended at 2.5 X 106 cells/ml in 
supplemented RPMI (Sigma) +10% FBS-HI, (supplementation: 75% sodium 
bicarbonate, 10 mM Hepes buffer, 100 µg/ml penicillin, 100 µg/ml streptomycin 
sulfate, 1.5 mM l-glutamine, and .00035% 2-mercaptoethanol).  LPS (Sigma # 
L6529) in 2% ethanol was added at a concentration of 1 µg/ml for mitogen 
stimulation.  GCR was tested by exposing aliquots of each suspension to 
dilutions of corticosteroid (0-5 µM, Sigma, St. Louis, MO, #C2505) dissolved in 
2% ethanol and supplemented RPMI.  Cell suspensions were placed in triplicate 
in flat-bottomed 96-well micro-titer plates in 100 µL aliquots and incubated for 
48-72 h at 37°C and 5% CO2.  After incubation, the cell survival assay was 
performed. 
  28 
 
Cell proliferation was assessed following the manufacturer’s instructions 
with the CellTiter 96 Aqueous non-radioactive proliferation assay kit from 
Promega (Madison, WI).  Color changes were quantified by optical density 
readings at 490 nm from an EMAX ELISA plate reader (Molecular Devices, 
Sunnyvale, CA).  Mean optical density values for the 3 replications for each 
sample were used, and the percentage of the corticosteroid-exposed cells 
versus the LPS stimulated cells was determined for statistical analysis.  
2.9.  Histological evaluation of CNS inflammation  
Brains and vertebral columns (containing intact spinal cord) were 
sectioned transversely into 4 and 12 pieces, respectively (see Campbell et. al., 
2001 for further detail).  Tissues were then processed for routine hematoxylin 
and eosin (H&E) staining.  Lesions of both the brain and spinal cord were scored 
in a similar manner by raters, blind to experimental condition.  Lesions evaluated 
included perivascular cuffing (accumulation of lymphocytes and macrophages 
around blood vessels), meningitis (accumulation of lymphocytes and 
macrophages in the meninges), and microgliosis (presence of increased 
microglia/macrophages within the parenchyma of the brain and spinal cord).  
Raters used stereo navigator software to assess the total perimeter and area 
available, and the percent of each effected by lesions.  Briefly, the perimeter was 
drawn around each slice or section of tissue, and closed.  This allowed the 
program to determine the length of the perimeter and the area enclosed.  For 
microgliosis, incidents of inflammatory cells were traced with a separately 
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defined line (to distinguish this data from the overall perimeter/area data), with 
multiple layers being traced over for as many layers of inflammatory cells as 
occurred.  For perivascular cuffing and microgliosis, the area affected is traced 
around (using a third line type), and enclosed.  Because perivascular cuffing and 
microgliosis often occur in close proximity, the entire area is used, and the area 
affected includes both types of inflammation.  
2.10.  Viral load and clearance 
Prior studies have shown that viral titers in CNS are maximal at 1-2 wk pi 
and by 3-4 wk pi the virus is apparently cleared to non-detectable levels (Welsh 
et al., 1987; 1989).  To evaluate the impact of SDR on CNS viral clearance, 
brains and spinal cords were removed on the day of sacrifice, homogenized, and 
stored at –80°C.  The viral content of the supernatant from the homogenized 
brains and spinal cords were determined by plaque assay on L2 cells (Welsh et 
al., 1987).  The plates were incubated at 37°C at 5% CO2 for 72 h, and then the 
plates were stained with .1% crystal violet to visualize the plaques that were 
formed.  Plates were scored based on the number of plaques formed on the L2 
cells and calculated per gram of tissue harvested (Welsh et al., 1987).  
2.11.  Statistical analyses 
Data are presented as mean + SEM.  Analysis of variance (ANOVA) was 
used to evaluate differences across SDR and infection conditions; and repeated 
measure ANOVA were used for analysis over time as appropriate.  These 
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analyses were followed by post hoc mean comparisons using Duncan's New 
Multiple Range Test.  For effect sizes, r2 was used.  
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3. EXPERIMENT 1 
3.1.  Introduction 
Experiment 1 examined the necessity of IL-6 by neutralizing this cytokine 
with antibodies.  This experiment had two steps.  The first determined if the 
antibody treatment (AbTx) was able to block IL-6.  Previous studies have also 
shown that SDR induced IL-6 does not interfere or alter SDR induced GCR.  
Therefore, we also examined the development of GCR prior to infection in these 
animals.  A 2 (AbTx, vehicle) x 1 (SDR) design was used for this step.  Once we 
established that IL- 6 was in fact elevated by SDR and blocked by the AbTx, a 2 
(SDR, NON) x 2 (AbTx, vehicle) design was used to examine how blocking IL-6 
with antibodies altered the effects of SDR on the acute phase of TMEV infection. 
3.2.  Methods 
3.2.1. Antibody to IL-6 
Polyclonal antibody to mouse IL-6 was purchased from R&D Systems 
(AF-406-NA, Madison, WI).  To provide the stock solution, the original 100 µg 
was dissolved in 1 mL sterile PBS.  The stock solution was then further diluted 
by 1:20 to result in a 5 ng/µL solution.   
3.2.2. Antibody administration   
The 5 ng/µL solution of neutralizing antibody was administered using a 
25-µL Hamilton syringe and a pump set to administer 60 µL/hour through a 36-g 
cannula (Plastics One, Roanoke, VA, C315IDC/SPC).  2 µL was then 
administered over 2 min, followed by a 30 s delay to prevent backwash of the 
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solution before the cannula was removed.  The total dose per animal was then 
10 ng.  This dose was based on the 50% neutralizing dose information provided 
by the manufacturer.  Control (NON-SDR) animals were administered mouse 
immunoglobulin (Ig, Santa Cruz Biotechnology, Inc #SC-2025) in the same 
volume of sterile saline as the vehicle, in order to account for generalized 
responses to proteins.   
3.2.3. Efficacy of antibody treatment in blocking IL-6   
In order to assess the efficacy of the antibody dose in blocking SDR 
induced IL-6, 12 mice were used.  These animals arrived from breeder, were 
cannulated and underwent SDR as described in the general methods section.  A 
1 (SDR) x 2 (AbTx, vehicle) was used.  At 1300-h daily, 4-h prior to SDR, 
antibody or vehicle administration occurred.  Following AbTx/SDR sessions, all 
animals were sacrificed and spleens were harvested for GCR assessment, while 
brain tissue and sera were assessed for IL-6 levels, using an ELISA assay 
(timeline for these procedures is depicted in Fig 3.2..1.). 
3.2.4. IL-6 ELISA   
ELISA for IL-6 assay was purchased from R & D Systems (R & D 
Systems Madison, WI), and sera (frozen at -80°C between sacrifice and the time 
of the assay) was assessed according to the manufacturer’s instructions.  Brain 
tissue was homogenized in 1 mL of Dulbecco’s Eagle Medium (Sigma) and flash 
frozen.  Tissue was stored at  -80°C until the time of the assay.  Tissue was then  
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Fig 3.1.  Procedure for Verification of Antibody to IL-6. 
Time line for all experimental procedures for the verification of the 
antibody to IL-6 in blocking IL-6 activity in Experiment 1. 
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thawed, centrifuged at 2000 rpm for 5 min.  50 µL of the supernatant per well 
was used to assess IL-6 levels in the brain. 
3.2.5. Procedure 
Upon arrival, mice were weighed and caged individually.  The next 
morning, cannulation surgeries occurred.  Mice were allowed to recover in 
individual housing for 2 d.  On pnd 27, mice were weighed again and assigned  
to cages in a counterbalanced manner, based on weight.  The Tylenol water was 
removed and sucrose and plain water were added for each cage.  Baseline 
measures were taken during this time period, with the exception of footprint.  On 
pnd 30-36, antibody or vehicle was administered daily beginning at 1300, and 
then the stressed animals were administered SDR at from 1700-1900.  After the 
final SDR session, at 2100, all mice were infected.  Illness measures were then 
taken through day 7 pi on all animals.  Motor function measures were taken only 
in those animals sacrificed at 21 pi.  Mice were sacrificed at either day 7 pi or 
day 21 pi, for either viral clearance or histology.  Mice sacrificed on day 7 pi for 
viral clearance were also tested for GCR.   The timeline events table for all 
procedures for this experiment are depicted in Table 3.1. 
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Table 3.1..  Procedural Event Table: Experiment 1. 
Arrive                                 
Surgery                                 
Weigh/ 
Assign 
                                
Open Field 
Habituation 
                                
Open Field 
Baseline 
                                
Illness 
Behaviors 
                                
AbTx                                 
SDR                                 
Footprint- 
Baseline 
                                
INFECT                                 
Motor -B                                 
Sacrifice- 7                                 
Footprint- 
20 
                                
Sacrifice - 
21 
                                
                                  
PND 23 24 26 27 29 31 33 35   37             
PI                 0   3 5 7 14 20 21 
 
 
 
 
Time line of all experimental procedures in Experiment 1, blocking IL-6 with 
neutralizing antibody to IL-6. 
 
 
Table 3.1.  Procedural Event Table: Experiment 1. 
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3.3. Results 
3.3.1. Verification of antibody treatment   
In order to verify that IL-6 was elevated due to SDR in the current study, and that 
this elevation was blocked by the neutralizing antibody treatment, an ELISA for 
IL-6 was used to test both sera and brain homogenate.  Figs 3.2.A and 3.2.B 
depict IL-6 levels in brain homogenate and sera, respectively.  ANOVA 
confirmed that SDR alone elevated IL-6 levels, and antibody treatment 
effectively reduced free IL-6, F (1,9) = 11.974, p < .01 in brain homogenate, and 
F (1.9) = 9.783, p < .05 in sera.  In addition, GCR developed normally in 
response to SDR, regardless of antibody treatment (Fig 3.2. C).  ANOVA verified 
that no significant reduction in proliferation of spleen cells occurred across 
increasing corticosteroid treatment, F (4,32) = 1.733, p = .2, indicating that SDR 
induced GCR.  Finally, there was no interaction between corticosteroid 
concentration with antibody treatment, F (4,32) = 1.508, p = .16, or main effect 
for antibody treatment, F (1,8) = .048, p = .8. 
3.3.2.  Illness measures   
Illness measures were assessed by analysis of data either within the first 
24 h pi, or comparing data collected in the first 24 h pi to pre-infection data.  The 
next five figures will present a series of illness-measure related data.  Measures 
taken included body temperature, percent sucrose preference (as a measure of 
anhedonia, body weight, activity in an open field, and mechanical sensitivity.  
Overall, the SDR-VEH animals had equal or greater illness behaviors compared 
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Fig 3.2.  Verification of Neutralizing Antibody to IL-6 Treatment.   
Panels A and B are IL-6 levels in brains and sera, respectively, 
following SDR, but prior to infection.  Panel C shows GCR prior to 
infection, the line is at 80% cell survival.  Asterisks (*) indicate 
significant differences of SDR-AbTx compared to group not exposed 
to the SDR-VEH group. 
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to animals that did not receive SDR.  In contrast, treatment with antibody to IL-6 
blocked the effects of SDR, and occasionally infection.   
3.3.2.1. Body temperature.  Body temperature (°C) was examined 12 h 
pre-infection and 12 h pi (Fig 3.3.).   Following infection, only the SDR-AbTx 
animals had significant change from pre-infection levels.  ANOVA confirmed a 3-
way interaction (SDR x AbTx x time), F (3, 98) = 5.925, p < .05.  Post hoc 
comparisons determined that the interaction was primarily due to the elevation in 
body temperature in the SDR-AbTx animals, while significant changes in body 
temperature were not evident in the other groups. 
3.3.2.2. Sucrose preference.  Sucrose preference was examined daily, as 
infection is usually associated with a loss of interest in pleasurable activities.   
Within the first 7 days pi, the SDR-VEH group has significantly less preference  
for sucrose water, and the antibody treatment (SDR-AbTx) restored sucrose 
preference (Fig 3.4.).  ANOVA confirmed a 2-way interaction (SDR x AbTx), F 
(1, 30) = 18.396, p < .001.  Post hoc means comparisons showed that the 
SDR-VEH group had significantly less preference compared all three other 
groups. 
3.3.2.3. Body weight.  Body weight loss is a common side effect of 
infection, therefore, body weight was monitored pre-infection and 12 h pi.  
Significant body weight loss occurred within 12 h pi, in all groups except the 
SDR-AbTx animals (Fig 3.5.).  A 3-way interaction (SDR x AbTx x time) was 
confirmed with ANOVA, F (3, 98) = 6.304, p < .05.  In addition, a significant 
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Fig 3.3.  Body Temperature. 
Body temperature changes pre-infection compared to post-
infection in all groups (n = 24 per group).  Only the SDR-AbTx 
group had a significant change in body temperature.  Pre-
infection, SDR combined with antibody treatment appeared to 
induce hypothermia.  This hypothermia was resolved post-
infection, in this group.  Significant differences are indicated 
with asterisk (*). 
 * 
 * 
NON-VEH NON-AbTx SDR-VEH SDR-AbTx
30
31
32
33
Pre-infection 12 h post-infection
 
  40 
 
 
%
 S
uc
ro
se
 P
re
fe
re
nc
e 
Fig 3.4. Sucrose Preference. 
Sucrose preference was assessed by percentage of total fluid 
intake during the first 24-h pi.  All cages included in the 
analysis met a criterion of a minimum of 60% sucrose 
preference prior to infection to be included in the analysis.  The 
SDR-VEH group was the only group to loose sucrose 
preference post-infection.  All other groups, including the SDR- 
AbTx group maintained a preference for sucrose water. 
Significant differences are indicated with asterisk (*). 
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Fig 3.5. Body Weight. 
Body weight loss was determined by comparing pre-infection 
weights (open bars) to post-infection weights (closed bars).   
All groups lost a significant amount of weight post-infection with 
the exception of the SDR-AbTx mice.  No between group 
differences were found.  Significant differences are indicated 
with asterisk (*). 
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main effect of time, F (1, 101) = 3.782, p < .0001, indicated that body weight was 
reduced in all groups post-infection.  However, post hoc comparisons revealed 
that while most animals lost significant weight post-infection, weight loss was not 
significant in the SDR-AbTx group.  
3.3.2.4. Activity.  Activity level is commonly reduced due to infection, and 
animals are less likely to explore the center area of the open field.  The change 
from baseline activity at day 1 pi was examined here to investigate this 
phenomenon (Fig 3.6. A and B respectively).  ANOVA verified a significant 2-
way interaction on horizontal activity (SDR x AbTx), F (1, 44) = 20.141, p < 
.0001.  In addition, a significant 2-way interaction (SDR x AbTx) also occurred 
for center time F (1, 44) = 4.610, p < .05. Post hoc comparisons found that the 
SDR-VEH group lost significantly more activity from baseline compared to the 
other groups.  In addition, the SDR-AbTx group had significantly less loss of 
activity compared only to the SDR-VEH group, indicating a recovery of activity 
level to normal levels. 
3.3.2.5. Mechanical sensitivity.  Infection is often associated with 
enhanced mechanical sensitivity.  Sensitivity to the mechanical stimulus, von 
Frey filament, was examined within the first 24 h pi (Fig 3.7.).  ANOVA verified a 
significant 2-way interaction (SDR x AbTx), F (1, 44) = 13.765, p < .001.  Post 
hoc comparisons found that the SDR-VEH group became significantly more 
sensitive compared to the other groups.  The SDR-AbTx group also became  
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Fig 3.6. Activity: Illness Related. 
Activity in the horizontal plane was taken as a measure of activity (A), as well 
as time spent in the center (B) both of which are often reduced due to illness.  
The graph depicts the change from baseline activity.  The SDR alone (SDR-
VEH) group had significantly reduced activity levels compared to the non-
stressed groups.  In contrast, the antibody treatment (SDR-AbTx) reversed 
the activity reductions due to SDR. Significant differences are indicated with 
asterisk (*). 
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Fig 3.7. Mechanical Sensitivity: Illness Related.  
Mechanical hypersensitivity was expected to develop within 24-h 
post infection.  In the SDR-VEH animals, this was what occurred.  
The graph depicts the change from baseline at day 1 pi on 
sensitivity to von Frey filament stimulation.  Only the SDR-VEH 
group developed greater sensitivity, compared to the other groups.  
Significant differences were noted with an asterisk (*). 
* 
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significantly less sensitive compared only to the SDR-VEH group, indicating a 
recovery of activity level to normal levels. 
3.3.3. Motor impairment measures  
TMEV infection causes a polio-like impairment in early infection, 
particularly in the Balb/cJ strain.  Motor impairment was assessed by examining 
multiple measures, including hind limb impairment, reduced mechanical 
sensitivity, horizontal activity, vertical activity, and stride length.  These 
measures are presented in the next five graphs.  By examining a panel of 
motoric impairment measures, converging lines of evidence confirmed that 
motoric impairment occurred in the SDR alone animals (SDR-VEH), as in 
previous studies.  In contrast, SDR plus antibody treatment against IL-6 (SDR-
AbTx) reduced motor impairment to non-stressed levels or better. 
3.3.3.1. Hind limb impairment score.  Hind limb impairment was examined 
using a scoring system that has previously been shown to be sensitive to the  
changes in impairment in early TMEV infection in Balb/cJ mice (Johnson et al., 
2004).  The effect of SDR and antibody against IL-6 on HLI was assessed 
through day 18 pi.  SDR exacerbated infection related hind limb impairment, 
while antibody against IL-6 reduced this impairment (Fig 3.8.).  ANOVA 
confirmed a main effect of SDR, F (1,52) = 69.227, p < .0001.  Additionally, a 3-
way interaction (SDR x AbTx x Day pi) indicates that HLI levels were restored to 
better than non-stressed infected animals over time by blocking IL-6 during  
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Fig 3.8. Combined Hind Limb Impairment: Experiment 1. 
Hind limb impairment scores have proven to be a reliable 
indictor of the motor impairment that develops as a result of 
TMEV infection.  The man graph above depicts the 
development of hind limb impairment scores over the course 
of time.  The inset depicts these data collapsed over time.  
The SDR-VEH group developed significantly greater 
impairment compared to the other groups.  In addition, the 
SDR-AbTx group had significantly less impairment by days 
11 and 18 pi.   Asterisks (*) indicate significant effects. 
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SDR, F (4,200) = 4.92, p < .001.   Post hoc comparisons determined that the 
SDR-VEH animals had significantly elevated impairment at every time point 
compared to all other groups.  The SDR-AbTx group also had significantly less 
impairment compared to non-stress groups at days 11 and 18 pi.   
3.3.3.2. Mechanical sensitivity.  Von Frey measures sensitivity to non-
noxious mechanical stimuli, using filaments of increasing size and pressure 
needed to bend the filament.  When animals require larger filaments than 
control, NON-SDR, animals before making a response, then either sensory or 
motoric impairment can be inferred.  Therefore, the SDR-VEH animals were 
expected to develop decreasing sensitivity, corresponding to increasing size of 
filament needed to elicit a response.  ANOVA confirmed a 3-way interaction 
(SDR x AbTx x Day pi) interaction, indicating that the SDR-VEH animals did in 
fact develop decreasing sensitivity over the course of infection (Fig 3.9.), F 
(3,132) = 11.763, p < .0001.  In addition, a main effect for antibody treatment 
alone, F (1,44) = 4.757, p < .05, and a 2-way interaction (SDR x AbTx) were also 
shown through ANOVA, F (1,52) = 6.169, p < .05.  Post hoc comparison 
indicated that the SDR-VEH group was significantly less sensitive compared to 
all other groups at both day 14 and 20 pi.  Finally, the SDR-AbTx group was not 
significantly different from the non-stressed groups at any time point, and these 
three groups (NON-VEH, NON-AbTx, and SDR-AbTx) did not change over time. 
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Fig 3.9. Mechanical Sensitivity: Impairment Related, Experiment 1. 
Motor impairment related mechanical sensitivity was examined over 
the course of infection.  These data are presented as a change from 
baseline.  Only the SDR-VEH group changed over time, and was 
significantly reduced immediately post infection (see Fig 4..5), 
however over the course of infection, these animals became less 
sensitive compared to the other groups, indicating either a motor or 
sensory impairment.  Asterisks (*) indicate significant differences, 
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Fig 3.10. Activity Measures: Experiment 1. 
Horizontal activity (A), and vertical activity (B) were both 
analyzed as change from baseline activity levels.  Horizontal 
activity indicates overall motor impairment, while vertical 
activity is more relevant to hind limb impairment.  SDR-VEH 
mice had significantly reduced activity in both planes, while 
the antibody treatment reverse these deficits.  Significant 
differences are indicated with asterisks (s). 
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  3.3.3.3. Open field activity.  Open field activity was assessed as a change 
from baseline in both the horizontal and vertical planes.  Analyses of open field 
activity found deficits in both horizontal (Fig 3.10.A) and vertical activity (Fig 
3.10.B) due to SDR treatment, and these deficits were reversed when the SDR 
animals were treated with antibody to IL-6.  An ANOVA confirmed a 2-way 
interaction (SDR x AbTx) on both horizontal, F(1,44) = 11.436, p = .01, and 
vertical activity F(1,44) = 7.784, p = .01 .  Post hoc means-comparisons showed 
that SDR-VEH was significantly less active compared to the other groups, while 
the SDR-AbTx not only reversed the effects of SDR alone.  Interestingly, SDR-
AbTx restored both horizontal and vertical activity levels to above baseline over 
the course of infection.  Post hoc comparisons also indicated that the SDR-
AbTx group was significantly more active in both the horizontal and vertical 
plane compared to the non-stressed groups. 
3.3.3.4. Stride length.  A final measure of motoric impairment, stride 
length, at day 20 pi has previously been shown to be reduced in SDR animals, 
(Johnson, et al; 2004).  Here, stride length at day 20 pi was again assessed.  
These data are presented in Fig 3.11.  An ANOVA confirmed main effects of 
both SDR, F (1,39) = 6.918, p < .05 and antibody treatment, F (1,39) = 12.286, p 
< .01.  A 2-way interaction (SDR x AbTx) was also found, F (1,39) = 5.335, p < 
.05.   Post hoc means comparison showed that the SDR-VEH animals had 
significantly greater deficits compared to all other groups, indicating that while  
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Fig 3.11. Stride Length: Experiment 1. 
Stride length will become reduced in the presence of motor 
impairment.  Only the SDR-VEH group developed 
significant deficits in stride length.  Antibody treatment 
reversed these effects.  An asterisk (*) indicates significant 
differences. 
  52 
 
SDR alone induced a deficit, AbTx was able to restore stride length to normal 
levels due to infection alone.  Fore limb data was similar (data not shown). 
3.3.4. Glucocorticoid resistance 
GCR developed prior to infection (Fig 3.2.C).  Resistance was again assessed in 
the animals sacrificed at day 7 pi.  Fig 3.12. depicts the results of this analysis, 
and indicates that GCR was able to persist in the antibody treated animals.  
ANOVA analysis confirmed a significant 3-way (SDR x AbTx x Corticosteroid 
dose) interaction, F (4,32) = 3.876, p < .01.  Post hoc analysis indicated that 
while SDR-VEH animals had significant, corticosteroid dose dependent 
reductions in proliferation, the SDR-AbTx group did not have significant 
reductions in cell survival, regardless of corticosteroid dose. The non-stressed 
groups also had significant dose-dependent reductions in cell survival, however, 
GCR would not be expected in these groups, either prior to infection or at day 7 
pi. 
 3.3.5. Immunological measures 
Various measures of the immunological effects of SDR and antibody to 
IL-6 treatment were collected to examine the physiological effects for this 
experiment, and these are depicted in the next three graphs.  Fig 3.13. depicts 
spleen and thymus weights.  A reduction in weight in these two immunological 
organs is an indirect indication of reduced immunological function.  Viral 
clearance (Fig 3.14.) in brain and spinal cord was assessed, because a failure to 
effectively clear the virus in the acute phase is a primary risk factor for  
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Fig 3.12. Glucocorticoid Resistance at day 7 pi: Experiment 1. 
GCR development in Experiment 1 at day 7 pi is shown.  Both SDR 
groups developed GCR prior to infection (Fig 4C).  However, only 
the antibody treated animals maintain resistance at day 7 pi.   
Asterisks (*) indicate significant post hoc differences compared to 
control (LPS-stimulated only) cells.   
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developing the chronic phase of TMEV infection, a model of MS (Oleszak et al., 
2004).  Finally, inflammatory cell infiltrate (Fig 3.15.) in both brain and spinal 
cord was examined because the acute phase of TMEV infection is primarily a 
CNS-inflammatory process.  Excessive inflammation may indicate the severity of 
the acute phase of TMEV disease.  Additionally, greater cytokine activity would 
also increase inflammation, so elevated inflammation can also be used to infer 
greater cytokine activation. 
3.3.5.1. Organ weights.  Spleen and thymus weights were collected at 
both day 7 and 21 pi.  Both days had similar pattern of results, therefore, only 
day 7 pi are shown.  In spleens, ANOVA confirmed a main effect for SDR, F 
(1,32) = 39.325, p < .0001, and this is depicted in Fig 3.13.A.  Post hoc 
comparisons indicated that SDR lead to increased spleen weights.  This SDR 
induced splenomegoly has been associated with the development of GCR 
(Avitsur et al., 2001).  GCR has typically disappeared by day 7 pi due to infection 
in our previous studies (Johnson et al., 2004).  However, GCR was maintained 
in the SDR-AbTx animals, but not the SDR-VEH animals or the non-stressed 
animals (Fig 3.12.).   
The thymus is responsible for processing T-cells, and a reduction in 
thymic weight may indicate a reduction in T-cell efficacy or numbers.  Viral 
clearance in the acute phase of TMEV infection is reliant upon cytolytic T-cells 
(CD8+); therefore, a reduction in either function or number of T-cells would be 
detrimental to viral clearance (Borrow et al., 1992).  Day 7 pi thymic weights are  
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Fig 3.13.  Immune Organ Weights: Experiment 1. 
Panel A depicts spleen weights.  Splenomegoly is associated with SDR 
induced GCR.  Both SDR groups have enlarged spleens compared to the 
non-stressed groups.  Panel B depicts thymus weights.  The SDR-VEH 
group had significantly atrophy of the thymus.  Asterisks (*) indicate 
significant differences. 
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depicted in Fig 8.1 B.  ANOVA confirmed a 2-way interaction (SDR x AbTx) for 
thymic weights at day 7 pi, F (1,32) = 5.777, p < .05.  Post hoc comparisons 
found that SDR alone significantly reduced thymic weights, while SDR-AbTx 
animals did not differ from the non-stressed groups.   
3.3.5.2. Viral clearance.  Examining viral titers in one subset at day 7 pi 
and in a second subset at day 21 pi assessed viral clearance.  Previously, our 
work has shown that viral clearance was altered by SDR alone (Johnson et al., 
2004).  Viral clearance in brain (Fig 3.14.A) and spinal cord (Fig 3.14.B) was 
again impaired by SDR treatment, and restored beyond normal levels in SDR-
AbTx animals.  ANOVA confirmed a 3-way interaction (SDR x AbTx x Day pi) for 
viral clearance in both brains, F (1,40) = 22.706, p < .0001, and spinal cords, F 
(1,40) = 38.022, p < .0001.  Post hoc comparisons indicate that the non-stressed 
groups significantly cleared virus from day 7 to day 21 pi, while the SDR-VEH 
animals had no significant change over time.  Finally, the SDR-AbTx group had 
a significantly reduced viral titer over time, indicating that the AbTx restored viral 
clearance in the SDR animals.   
3.3.5.3. Inflammation.  Inflammation (Fig 3.15.) was assessed in brains 
and spinal cords by measuring the percentage of the perimeter affected by 
meningitis (microglia and macrophage infiltrate into the meninges) and the 
percentage of area affected by microgliosis and perivascular cuffing (microglia 
and macrophage infiltrate in the white and/or grey matter).  As in previous  
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Fig 3.14. Viral Clearance: Experiment 1. 
Viral titers were taken from spinal cord (A) and brain (B) at days 7 
and 21 pi.  A reduction of viral load over time indicates viral 
clearance.  All groups cleared a significant amount of virus over time 
with the exception of the SDR-VEH group.  Significant differences 
are indicated with asterisks (*). 
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Fig 3.15. Inflammation: Experiment 1. 
Inflammation (as a % of perimeter) in the spinal cord (A) and 
brain (as a % of area) was elevated by SDR alone (SDR-VEH) 
group.  This occurred across both days 7 and 21 pi, in both 
compartments.  Asterisks (*) indicate significance. 
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studies, SDR caused greater inflammation in both brains and spinal cords. 
ANOVAs found a 2-way (SDR x AbTx) interaction in brains, F (1,40) = 24.187, p 
< .0001 and spinal cords, F (1,40) = 19.091, p < .0001.  This elevation in 
inflammation continued to be significant at both day 7 and 21 pi.  Post hoc 
comparisons indicate that SDR alone significantly elevated inflammation at both 
day 7 and 21 compared to the other three groups.  In addition, SDR-AbTx had 
greater inflammation compared to non-stressed groups, at day 7 pi, but not at 
day 21 pi.    
3.3.6. Summary of results 
 We examined batteries of illness measures, motor impairment measures, 
and physiological measures.  These results are summarized in Table 3.2.  
Overall, SDR alone (the SDR-VEH group) increased illness measures, motor  
impairment, and physiological aspects of disease.  In contrast, when SDR 
animals were treated with neutralizing antibody to IL-6, the negative effects of 
SDR were reversed.  In both the illness and motor impairment measures, the 
SDR-AbTx animals had lower levels of disease indication than the non-stressed 
groups. 
3.4.  Discussion   
Previous studies found that prior exposure to social stress exacerbates acute 
and chronic TMEV infection.  The aim of Experiment 1 was to determine the 
necessity of SDR induced IL-6 on acute TMEV infection.  Since previous studies 
also found that SDR causes excessive inflammation and deregulates GC control 
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Table 3.2. Summary of Results: Experiment 1 
 
  
NON-
VEH 
SDR-
VEH 
NON-
AbTx 
SDR-
AbTx 
Illness Measures 0 ↑↑ 0 ↓ 
Body temperature 0 0 0 ↓↓ 
Sucrose preference 0 ↑↑↑ 0 0 
Body weight ↑ ↑↑↑ ↑↑ 0 
Horizontal activity 0 ↑↑↑ 0 ↓↓ 
Mechanical sensitivity 0 ↑↑↑ 0 ↓↓ 
          
Motor impairment measures 0 ↑↑↑ 0 ↓ 
Hind limb impairment score 0 ↑↑↑ ↑ ↓↓ 
Mechanical sensitivity 0 ↑↑↑ 0 0 
Horizontal activity 0 ↑↑↑ 0 ↓↓ 
Vertical activity 0 ↑↑↑ 0 ↓↓ 
Stride length 0 ↑↑↑ 0 0 
          
Physiological measures 0 ↑↑↑ 0 0 
Spleen weight 0 ↑↑ 0 ↓↓ 
Thymus weight 0 ↑↑↑ 0 0 
Viral clearance: Brain 0 ↑↑↑ 0 ↓↓ 
Viral clearance: Spinal cord 0 ↑↑↑ 0 ↓↓ 
Inflammation: Brain 0 ↑↑↑ 0 0 
Inflammation: Spinal cord 0 ↑↑↑ 0 0 
 
 
 
 
 
 
 
Table 3.2. presents a summary of the results found across illness, motor 
impairment and physiological measures of TMEV infection.  The control, non-
stressed, vehicle treated groups was assigned 0, as an indicator of normal 
disease level.  When a group exhibited increased disease severity on a given 
measure, this was indicated by ↑ (p > .05) or ↑↑ (p > .01), or ↑↑↑  (p > 
.0001).  In contrast, when a group exhibited reduced disease severity, this was 
indicated by ↓ (p > .05) or ↓↓ (p > .01).  The bold lines are a summary of the 
results for each set of measures. 
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of inflammation, the pro-inflammatory cytokine, IL-6 is a likely mechanistic 
molecule (Johnson et al., 2004).  Antibody to IL-6 was used to antagonize IL-6 
release due to SDR.  Initially, the efficacy of the neutralizing antibody was 
confirmed, reducing IL-6 activity by 75-to-90% (Fig 3.2.).  As in previous studies, 
the current study found that SDR alone was associated with more severe illness, 
motor impairment, and physiological measures of TMEV infection.  Blocking the 
SDR-induced IL-6 restored illness, motor impairment, and physiological 
measures to normal (infected but non-stressed) levels in acute TMEV infection.  
Thus, IL-6 appears to be necessary for the negative effects of SDR in acute 
TMEV infection.  These findings were internally consistent, as well as 
convergent with previous SDR studies, however a few exceptions occurred.  
First, antibody to IL-6 prevented the resolution of GCR by day 7 pi as occurred in 
previous studies.  Second, infection related hypothermia or fever developed 
differently than expected.  Finally, immunological measures were convergent but 
not consistent with previous studies using SDR in acute TMEV infection. 
One of the consistent hallmarks of SDR is the development of GCs 
resistance.  In the past, TMEV infection was associated with the loss of GCR by 
day 7 pi.  In the current study, SDR induced GCR prior to infection, and the 
development of GCR was not altered by administration of neutralizing antibody 
to IL-6.  In addition, the SDR alone animals also lost GCR by day 7 pi as 
occurred in past studies.  However, at day 7 pi, the antibody treated animals 
maintained GCR.  These data are somewhat difficult to interpret, given that the 
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signaling pathway for the release of the GCR macrophages from the bone 
marrow is not well elucidated.  One possible explanation may be that blocking 
IL-6 may also interfere with some signaling pathways for the release of the GCR 
macrophages.  The most likely candidate would be that similar to the HPA-axis, 
IL-6 can also trigger the SAM-axis, given that norepinephrine may be the 
signaling molecule that causes the GCR macrophages to traffic to the bone 
marrow.  
Body temperature deregulation is dependent upon several factors in 
mice, only one of which is IL-6.  First, both the type of inflammatory stimuli and 
dose can alter development of fever or hypothermia.  A recent review found that 
overall, low doses of LPS are associated with hypothermia, while high doses 
result in fever, although the serotype of LPS used may also be important (Leon, 
2002).  Sepsis (induced by cecal ligation and puncture) results in hypothermia 
for the first 24 h, while fever occurred past that point (Leon et al., 1998).  
Turpentine-induced inflammation caused fever (Horai et al., 1998).  Finally, two 
out of six strains of avian flu induced fatal hypothermia in mice (-4°C), one of the 
strains induced a milder hypothermia (< 2°C), and the other three strains did not 
alter body temperature.    
These temperature regulation effects may be differentially mediated 
through IL-6 (as well as other cytokines).  Turpentine induced fever is attenuated 
in both IL-1 and IL-6 knockout mice.  In LPS studies, IL-6 knockouts develop 
mild hypothermia (approximately -.5°C) that persists for at least 12 h at low 
  63 
 
doses, while wild type mice developed fever.  In contrast, fever developed 
equally in both IL-6 knockouts and wild type mice at high doses of LPS (Kozak 
et al., 1998). Given that the majority of studies show hypothermia at the same 
low dose used in the IL-6 knockout mice, this data is difficult to interpret.  If the 
LPS had induced hypothermia, it is possible that knocking out IL-6 genes would 
have no effect here as well.  
In the current studies, body temperatures were taken 12 h prior to 
infection and 12 h pi, but only the antibody treated-SDR animals had altered 
body temperature across the two time points.  Prior to infection, the antibody 
treated- SDR animals had body temperatures that averaged 1- 1.5 ºC below the 
other animals.  Thus, blocking IL-6 induced hypothermia in the absence of 
infection.  Post infection, these same animals’ body temperatures became 
elevated by an average of over 1 ºC compared to pre-infection, returning these 
animals to the same temperature range as the other groups.  Interpreting this 
data is difficult, because antibody treatment appears to have reduced body 
temperature significantly, while infection overwhelmed this reduction and 
returned body temperature back to the range of the remaining mice, stressed or 
not.  
One possible explanation may be due to the unique role of IL-6 in HPA-
axis activation.  As noted earlier, IL-6 also stimulates the HPA-axis, deregulating 
the negative feedback loop, and increasing the overall levels of corticosteroids 
(Bethin et al., 2000).  By blocking IL-6, the negative feedback loop of the HPA-
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axis may be re-instated resulting in an overall reduction in corticosteroids.  If 
corticosteroids are reduced (through the self-regulating negative feedback loop), 
then the other proinflammatory cytokines (IL-1, TNF-α) would have even less 
regulation (especially in light of the GCR that is in place at this time).  IL-1 is 
known to mimic LPS, so an increase in this cytokine could possibly induce the 
pre-infection hypothermia (Leon, 2002).  Since the antibody to IL-6 treatment 
has a half-life of no longer than 10 h (according the manufacturer), the antibody 
would have been reduced by at least half at 2 h pi.  Therefore, infection induced 
IL-6 at 12 h pi could be stimulating the HPA-axis, allowing GCs to regulate the 
other cytokines and thus, return body temperature to normal.    
Although this is a reasonable explanation, there are a few flaws in the 
argument.  First, antibody treatment in the absence of stress did not induce the 
pre-infection hypothermia.  However, this may be because the other cytokines 
that might induce hypothermia were not activated in the absence of stress.  
Second, we know that an important source of both IL-6 and the other 
proinflammatory cytokines are the macrophages and microglia.  Since GCR 
occurs in the splenic macrophages, the CNS microglia may also be resistant at 
the time of infection, leading to excessive proinflammatory cytokine release.  We 
also know that in the antibody to IL-6 treated animals that GCR persists through 
day 7 pi.  Thus, the return of cytokines back under GCs control is unlikely at the 
time these data were collected.  Thirdly, SDR was associated with the 
development of all of the other sickness measures and blocking IL-6 restored 
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these measures back to normal.  Therefore, it would be counter intuitive to 
deduce that antibody treatment did the opposite only on body temperature.  
While the data indicates that IL-6 is necessary for development of the majority of 
sickness behaviors, fever did not converge with the other measures and this 
contradiction should be explored further.   
IL-6 appears necessary not only for the development of exacerbated 
sickness behaviors due to SDR in acute TMEV infection, but also motor 
impairment and immunological exacerbations previously noted.  However, the 
immunological data does differ somewhat from our previous work.  In past 
studies, we did not find splenomegoly post-infection due to SDR.  Since the 
increased spleen size was not associated with continued GCR in the SDR alone 
animals, this finding may be related to a stronger immune response.  As a 
primary immune organ, the spleen in the SDR animals may have been 
processing a greater number of monocytes and lymphocytes, but not resistant 
cells.   
In addition to enlarged spleen, the current study also found thymic 
atrophy.  In past studies using restraint stress, we have often found mild to 
extreme thymic atrophy, however we had not seen this in prior social stress 
studies (Campbell, et al., 2001; Johnson, et al., 2004).  The thymic atrophy in 
the current study was mild, but significant.  Considering the essential role of 
CD8+ T-cells for viral clearance (Oleszak et al., 2004), the thymic atrophy may 
also help explain the viral clearance findings.  In our previous studies, animals 
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exposed to SDR prior to infection had impaired viral clearance in the spinal 
cords, but also had lower titers at day 7 pi compared to non-stressed animals.  
Here, all groups had high titers at day 7 pi.  Since the thymic atrophy also 
occurred in the SDR animals here, perhaps the elevated titers at day 7 pi in the 
current study are related to thymic function.  In addition, in past studies, viral 
clearance occurred equally in both the SDR and non-stressed animals normally 
in brain tissue.  In the current study, viral clearance did not occur at all in the 
brains of the SDR group, and the other three groups cleared a smaller 
percentage compared to previous studies.  Thymic atrophy cannot fully account 
for the less effective viral clearance in the current study compared to past 
studies, since the atrophy only occurred in the SDR alone animals.  Perhaps the 
additional stress of surgery for cannulation impaired viral clearance for all of 
these animals, since layering on stressors can alter immune function. 
In addition, viral clearance was consistent with previous work, however 
the relationship between groups was not.  In past studies, exposure to SDR prior 
to infection resulted in spinal viral titers that were reduced approximately 25% at 
day 7 pi compared to non-stressed animals.  These animals failed to develop 
any further reduction over time.  In the current study, the spinal viral titers are 
not significantly different across groups, although the SDR alone animals once 
again failed to significantly reduce viral titers over time.  In addition, previous 
work found that viral clearance in the brain tissue occurred in all groups.  In 
contrast, the current study found that SDR alone resulted in a failure to clear a 
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significant amount of virus over time in both spinal and brain tissue.  The failure 
of the SDR groups to reduce viral titer in either brains or spinal cord tissue, at 
either day 7 or 21 pi, may be due to the increased inflammation that we also 
documented in these animals.  CD 8+ T-cells and B-cells are needed to clear 
the virus, but the excessive microglia and/or macrophage activation may prevent 
the appropriate signaling and trafficking of lymphocytes to the site of infection.  
This inflammation may be from two sources that act synergistically.  First, the 
cannulation surgery violated the blood-brain barrier, allowing many more 
macrophages to traffic into the CNS.  Second, SDR induced proinflammatory 
cytokines in microglia and possibly neuronal tissue (that may not be under GC 
regulatory control).  Cannulation alone was not sufficient to cause excessive 
inflammation.  In the absence of additional stimuli, the cytokine release due to 
cannulation surgery injury resolves within approximately 7 days, 2 weeks prior to 
the sacrifice in the current study (Holguin et al., 2005).  However, previous work 
has shown that both IL-6 and TNF-α may be elevated due to SDR alone.  
Therefore, cannulation, SDR, and infection combine to result in elevated 
inflammation that interferes with appropriate lymphocyte trafficking.   
Finally, the effect of SDR on inflammation resulted in greater effect size 
differences than in previous studies.   The effect size for the brain inflammation 
was .656 (considered a medium effect size) in the current study compared to 
.112 (no effect) for microgliosis and .26 (small effect) for perivascular cuffing in 
our previous work (Johnson et al., 2004).  For the spinal cord meningitis, the 
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current study had an effect size of .829 (large), compared to .251 (small) in our 
previous studies.  The difference in effect sizes may be due to several factors, 
including more sophisticated use of computerized assessment of the area 
affected by inflammation.  It is unlikely to be solely due to the cannulation 
procedure (because this was equated across groups), however this procedure 
may have increased the system’s vulnerability to inflammation associated with 
SDR.  
While there are differences between the original work and the current 
studies, the data from Experiment 1 is consistent in that SDR exacerbated acute 
TMEV infection, and impaired viral clearance.  Finally, the illness measures, 
motoric impairment measures and immunological measures all converge to 
indicate that blocking IL-6 blocks the exacerbation of TMEV infection due to 
SDR. 
 
  69 
 
4. EXPERIMENT 2 
4.1.  Introduction 
Experiment 1 resulted in the conclusion that IL-6 is necessary for the 
negative effects of SDR on acute TMEV infection.  In order to fully assess the 
role of IL-6 in the negative effects of SDR in acute TMEV infection, sufficiency of 
this cytokine also needed to be determined.  Thus, social disruption was 
replaced with exogenous IL-6, and the procedures from Experiment 1 were 
replicated.   
4.2.  Methods 
4.2.1. IL-6 substitution   
Mouse IL-6 was purchased from R&D Systems (406-ML-005/CF).  5µg 
was dissolved in 1 mL sterile PBS.  This stock solution was diluted by 1:50 in 
PBS for administration.  A volume of 2 µl in 2 min was administered, for a dose 
of 200 pg per animal, based on the control (NON-SDR) animal IL-6 levels from 
the efficacy part of Experiment 1.  Cytokine was administered at 1600-h daily, 
while vehicle (sterile saline plus mouse Ig, Santa Cruz Biotechnology, Inc #SC-
2025) was administered to control (NON-SDR) animals. 
4.2.2. Procedure 
Upon arrival, animals were weighed and caged individually.  The next 
morning, cannulation surgeries occurred.  Mice were allowed to recover in 
individual housing for 2 days.  On pnd 27, mice were weighed again and  
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Table 4.1.  Procedural Event Table: Experiment 2. 
Arrive                                 
Surgery                                 
Weigh/ 
Assign 
                                
Open Field 
Habituation 
                                
Open Field 
Baseline 
                                
Illness 
Behaviors 
                                
IL-6 
treatment 
                                
Footprint- 
Baseline 
                                
INFECT                                 
Motor -B                                 
Sacrifice- 7                                 
Footprint- 
20 
                                
Sacrifice - 
21 
                                
                                  
PND 23 24 26 27 29 31 33 35   37             
PI                 0   3 5 7 14 20 21 
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assigned to cages in a counterbalanced manner, based on weight.  The Tylenol 
water was removed and sucrose and plain water were added for each cage. 
Baseline measures were taken during this time period, with the exception of 
footprint.  On pnd 30-36, exogenous IL-6 or vehicle was administered daily 
beginning at 1500.  On pnd 36 at 2100, all mice were infected.  Illness measures 
were then taken through day 7 pi on all animals.  Motor function measures were 
taken only in those animals sacrificed at 21 pi.  Mice were sacrificed at either 
day 7 pi or day 21 pi, for either viral clearance or histology.  Mice sacrificed on 
day 7 for viral clearance were also tested for GCR.   The timeline for all 
procedures for this experiment is depicted in Table 4.1. 
4.3.  Results 
4.3.1. Illness measures  
As in Experiment 1, illness behaviors were assessed by analysis of data 
either within the first 24 h pi, or comparing data collected in the first 24 h pi to 
pre-infection data.  Measures included body temperature,  mechanical 
hypersensitivity, sucrose preference, body weight, and activity in an open field.  
Overall, the IL-6 treatment significantly altered body temperature and 
mechanical sensitivity illness measures in comparison to vehicle treated controls 
(VEH), and these data are presented in Fig 4.1.  The other measures were not 
altered IL-6, and these are presented in Fig 4.2. 
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Fig 4.1. Illness Measures Altered by IL-6. 
Body temperature (A) and mechanical hypersensitivity (B) were 
the only measures altered by IL-6 treatment.  IL-6 caused 
significant hypothermia compared to baseline.  IL-6 also 
caused a significantly greater sensitivity to mechanical stimuli 
to develop post-infection.  Significant effects are indicated by 
asterisks (*). 
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Fig 4.2. Illness Measures Not Altered by IL-6. 
Sucrose preference was significantly reduced in the vehicle 
treated (A), but not in the IL-6 treated mice.  An asterisk (*) 
indicates the significant difference.  Neither body weight loss  
(B) nor horizontal activity (C) were altered by IL- treatment.  
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  Following infection, ANOVA revealed that the IL-6 treated mice had a 
significant temperature drop, F (1,46) = 20.15, p < .0001, and greater allodynia, 
F (1, 22) = 8.277, p < .01.  Post hoc comparisons determined that the IL-6 
treatment significantly reduced body temperature and increased mechanical 
sensitivity.  IL-6 treatment failed to alter body weight loss (p = .87) or activity 
reduction (p = .22).  The vehicle treated groups did develop a significant 
reduction in sucrose preference F (1, 9) = 5.114, p < .05.   
4.3.2. Motor impairment measures  
 As is Experiment 1, HLI, mechanical sensitivity, horizontal activity, 
vertical activity, and stride length were used to assess motor impairment, and 
these data are presented in the following four graphs (Fig 4.3.-6.).  IL-6 
treatment did not significantly alter hind limb impairment, F(1,22) = .6838, p = 
.68, mechanical sensitivity (p = .16), vertical activity F(1,22) = .002, p = .9, or 
stride length (p = .9).  In addition, ANOVA revealed a trend toward a reduction in 
horizontal activity in the IL-6 treated animals, F(1,22) = 3.864, p = .06.  Thus, IL-
6 alone had no significant effects on motor impairment that occurs during acute 
TMEV infection. 
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Fig 4.3. Combined Hind Limb Impairment: Experiment 2. 
Hind limb impairment was not altered throughout the course of 
the acute phase by IL-6 treatment 
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Fig. 4.4. Mechanical Sensitivity: Impairment Related, Experiment 2. 
IL-6 treatment did not alter mechanical sensitivity throughout the 
course of infection 
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Fig 4.5.  Activity Measures: Experiment 2. 
Horizontal (A) and vertical (B) activity are shown.  IL-6 treatment did not 
significantly alter either activity measure. 
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Fig 4.6. Stride Length: Experiment 2. 
Footprint stride length was examined.  IL-6 treatment did not alter 
stride length.  
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4.3.3. Immunological measures   
As in Experiment 1, spleen and thymus weights, viral titers over time (for 
viral clearance) in brain and spinal cord and inflammation in brain and spinal 
cord were examined as measures of the efficacy of IL-6 in mimicking SDR in 
acute TMEV infection.  These data are presented in the following three graphs 
(Fig 4.7.-9.).  As in the motor impairment measures, IL-6 treatment did not result 
in significant changes from controls (VEH).  ANOVA found no effect for IL-6 
treatment on spleen ANOVA found a main effect for time in brains, F (1,20) = 
5.62, p < .0001, and spinal cords, F (1,20) = 7.97, p < .0001, indicating that the 
virus was effectively cleared in both groups there was no difference between 
groups (p = .55).  ANOVA also found no significant differences between groups 
in inflammation in either brain or spinal tissue (p = .38). 
4.3.4. Summary of results 
 We examined batteries of illness measures, motor impairment measures, 
and physiological measures in order to assess the efficacy of IL-6 in mimicking 
the effects of SDR.  These results are summarized in Table 4.2.  Overall, IL-6 
increased disease indications of body temperature and mechanical sensitivity, 
illness measures.  However, there were no significant differences between the 
vehicle and IL-6 treated groups on the motor impairment and physiological 
aspects of disease.  
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Fig 4.7. Immune Organ Weights: Experiment 2. 
Immune organ weights were taken as a measure of immune 
function.  IL-6 treatment did not alter spleen (A) or thymus (B) 
weights.  
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Fig 4.8. Viral Clearance: Experiment 2. 
Viral clearance was determined by examining viral load at day 7 pi 
compared to day 21 pi.  Viral titers over time in the spinal cord (A) and 
brain (B) were not altered by IL-6 treatment.  Both groups had significantly 
reduced viral loads over time in both compartments.  
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Fig 4.9. Inflammation: Experiment 2. 
Meningitis was examined in the spinal cord (A), while perivascular 
cuffing and microgliosis were more common in the brain (B).  
Although a great deal of the inflammatory infiltrate was reduced 
over time, IL-6 treatment did not alter inflammation in either 
compartment at either day 7 or 21 pi.   
A.  
B.  
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 Table 4.2. Summary of Results, Experiment 2. 
  VEH IL-6 
Illness measures 0 ↑ 
Body temperature 0 ↑↑ 
Sucrose preference 0 0 
Body weight 0 0 
Horizontal activity 0 ↑? 
Mechanical sensitivity 0 ↑ 
      
Motor impairment measures 0 0 
Hind limb impairment score 0 0 
Mechanical sensitivity 0 0 
Horizontal activity 0 ↑? 
Vertical activity 0 0 
Stride length 0 0 
      
Physiological measures 0 0 
Spleen weight 0 0 
Thymus weight 0 0 
Viral clearance: Brain 0 0 
Viral clearance: Spinal cord 0 0 
Inflammation: Brain 0 0 
Inflammation: Spinal cord 0 0 
 
 
 
 
 
 
 
 
 
 
Table 4.2. presents a summary of the results found across illness, motor 
impairment and physiological measures of TMEV infection.  The control, 
vehicle treated groups was assigned 0, as an indicator of normal disease 
level.  When the IL-6 treated group exhibited increased disease severity on a 
given measure, this was indicated by ↑ (p > .05) or ↑↑ (p > .01), if the 
increased severity was marginal, this was indicated by ↑? (p < .05). 
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4.4.  Discussion 
In order to fully examine the role of IL-6 in the deleterious effect of SDR in 
acute TMEV infection, Experiment 2 aimed to elucidate the sufficiency of IL-6 in 
replicating those effects.  IL-6 treatment was able to somewhat increase 
sickness behaviors.  IL-6 decreased body temperature, and increased 
mechanical sensitivity to von Frey stimuli.  However, IL-6 treatment did not 
increase body weight loss due to infection, nor did it significantly alter activity 
levels compared to vehicle treated controls. Previous work on cytokine sickness 
syndrome indicated that IL-6 can independently induce body temperature 
changes but is not known to alter the other behaviors in the absence of IL-1β or 
TNF-α (Bluthe et al., 2000; Lenczowski et al., 1999).  Research examining 
allodynia (or increase sensitivity to non-noxious stimuli) also indicated that IL-6 
often induces hypersensitivity to mechanical and cold stimuli (Anderson and 
Rao, 2001; DeLeo et al., 1996; Vissers et al., 2005).  Taken as a whole, IL-6 
alone induced a milder sickness syndrome compared to SDR, but significantly 
greater than vehicle treated animals overall.  These data were consistent with 
previous work examining both IL-6 related cytokine sickness behavior and 
allodynia.  
IL-6 treatment prior to infection resulted in mild post-infection 
hypothermia.  This is consistent with many low-dose LPS and sepsis studies, 
that have also found hypothermia in mice (Leon, 2002).  Interestingly, one report 
has shown that IL-6 knockout mice also develop hypothermia in response to low 
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dose LPS (Kozak et al., 1998).  This conflict requires further investigation, 
however the nature of the infection (LPS vs. TMEV), or the route of infection 
(LPS is usually administered intraperitoneally, while TMEV is administered ic), or 
the cannulation surgery in the current study may be plausible factors.  Any 
combination of these factors may also result in the conflict in IL-6/hypothermia 
data found here and/or those found by Kozak and colleagues (1998).   
Cytokine mediated sickness behavior has been shown to be mediated by 
both IL-1β, and to a lesser degree, TNF-α (Espinosa and Bermudez-Rattoni, 
2001).  In contrast, IL-6 generally exacerbates sickness behaviors induced by 
other cytokines (Bluthe et al., 2000).  IL-6 has only been administered to rats in 
previous systematic sickness behavior studies, and these studies found that IL-6 
induced fever, but no other sickness behaviors independently (Lenczowski et al., 
1999).  Since LPS at low doses also induces fever in rats, but hypothermia in 
mice, these findings are consistent with the current findings (Leon, 2002).  
Although Lenczowski and colleagues (1999) did not find mechanical 
hypersensitivity or sucrose preference reduction, others have found that IL-6 
elevations (in response to infectious or stress stimuli) results in hypersensitivity 
to various non-noxious stimuli in both rats and mice (Anderson and Rao, 2001; 
DeLeo et al., 1996; Vissers et al., 2005) and IL-6 elevations in mice that fail to 
develop sucrose preference (Ballok et al., 2003; Sakic et al., 1997).  Taken 
together, these data indicate that sickness behaviors found in the current study 
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are consistent with those found in previous studies, although there is a paucity of 
data on the direct effects of IL-6 administration in mice. 
 In contrast to illness behaviors, IL-6 treatment was not sufficient to alter 
motor impairment development or the physiological development of acute TMEV  
infection compared to vehicle treated controls.  Thus, IL-6 was not shown to be 
sufficient to mimic the negative effects that SDR has on acute TMEV infection. 
However, the dose used here was based on our endogenous data from 
Experiment 1, and thus exploratory.  It is therefore possible that a higher dose 
would be more effective in mimicking SDR effects in TMEV infection. 
 The failure of IL-6 to mimic the effects of SDR is not surprising.  The 
effects of SDR are most likely multi-factorial.  While each factor may be 
necessary (such as IL-6), individually they are not sufficient.  SDR is associated 
with GCR, and GCR may be mediated by norepinephrine signally to the bone 
marrow, triggering the trafficking of the GCR macrophages to the spleen (Engler, 
et al., 2004).  Additionally, other cytokines may also be mediating the effects of 
SDR as well.  Therefore, at least GCs, catecholamines, and cytokines are 
possible factors in the effects of SDR on acute TMEV infection.  At this point, we 
know that IL-6 is necessary, but probably not sufficient.  In addition, IL-6, as well 
as other stress-induced cytokines may also influence the development of GCR, 
and through GCR alter TMEV infection.  Both the current work and previous 
studies have shown that removing IL-6 (by blocking IL-6 with neutralizing 
antibodies or IL-6 knockouts) does not alter GCR development (Stark, et al., 
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2002).  Although IL-6 may not be necessary, it may contribute to GCR or 
infection processes, if available within the organism.  However, other factors 
(such as norepinephrine) may be more essential.  Further investigation of the 
other suspect substances (i.e. other cytokines, catecholamines, corticosteroids) 
will continue to elucidate both the direct role of SDR on TMEV infection, as well 
as on GCR.   
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5. GENERAL DISCUSSION 
The current study sought to delineate the role of IL-6 in the negative 
outcomes associated with SDR in acute TMEV infection.  Past studies have 
demonstrated that exposure to SDR prior to infection led to elevated motor 
impairment, elevated inflammation, and altered viral clearance (Johnson et al., 
2004, Johnson et al., in submission).  In addition, GCR was present at the time 
of infection when SDR was administered prior to infection.  GCR results in 
deregulation in the production of proinflammatory cytokines, allowing 
inflammatory stimuli to persist.  The a priori hypothesis of this study was that 
inflammation, mediated through SDR induced GCR, may be responsible for the 
exacerbation of acute TMEV infection caused by SDR.  The proinflammatory 
cytokine, IL-6, was known to be elevated due to SDR, and was a likely 
biochemical mediator.  Fig 5.1. presents a theoretical model of possible 
pathways for SDR to alter TMEV infection. 
In the current study, SDR induced GCR, and the SDR alone animals in 
Experiment 1 had elevated sickness behaviors.  These animals developed 
increased mechanical sensitivity, anhedonia, and decreased motor behavior 
beyond that of the non-stressed animals.  In previous studies, GCR developed 
only in animals exposed to SDR prior to infection.  If SDR is administered 
coincident infection, GCR does not develop, and TMEV outcomes are less 
severe than in control (NON-SDR) animals (Johnson, et al., 2004).  Therefore, 
the development of GCR may be an essential mechanism for SDR to  
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Figure 5.1.  Theoretical Pathways for Effects of SDR on TMEV Infection. 
This diagram depicts the relationships of possible pathways through 
which SDR acts to exacerbate TMEV infection.  “A” represents pathways 
that are known based on Experiment 1.  “B” represents pathways that are 
known based on Experiment 2.  “C” represents pathways that are known 
based on Johnson, et al., 2004.  “?” indicate pathways that need 
elucidation. 
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exacerbate TMEV infection.  The role of GCR in TMEV exacerbation would be 
highly clinically relevant for MS (and possibly other inflammatory 
neurodegenerative diseases).  MS is associated with multiple pathologies, and is 
highly variable (Lublin and Reingold, 1996).  The vast majority of MS patients 
are defined as relapsing-remitting (80%), and these patients are primarily 
inflammatory in pathology (Noseworthy et al., 2000; Sospedra and Martin, 
2005).  Many patients with relapsing-remitting MS are also hyper-responsive to 
stress, resulting in a higher than expected release of cortisol (Fassbender et al., 
1998; Mohr and Pelletier, 2005).  Interestingly, chronic stress is associated with 
GCR in MS (Mohr and Pelletier, 2005).  Therefore, many MS patients have an 
inflammatory pathology combined with excessive cortisol release, and as stress 
often precedes MS exacerbations, they may also have GCR.  The GCs are 
known to be anti-inflammatory, through down regulation of the release of 
proinflammatory cytokines (Adcock, et al., 2004).  This leads to one theory of 
how stress might be associated with exacerbations of MS symptoms.  Once the 
stress resolves, cortisol release may return to baseline or even decline to below 
normal levels until the body can recover homeostasis.  During this refractory 
period, inflammation would be able to increase, increasing inflammatory 
mediated symptoms (Mohr and Pelletier, 2005).  If these patients have 
developed GCR, then stress will result in excessive release of GCs, but they 
would be less effective in suppressing inflammation.  Since the refractory period 
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would still occur, those cells that still responded to GC regulation would lose 
those immunosuppressive effects as well.    
Furthermore, exogenous GCs are often used pharmacologically to help 
ameliorate inflammatory MS symptoms.  For those patients that are resistant, 
GC treatment would be significantly less effective, and may even have negative 
effects.  Excessive exposure to GCs can cause excitotoxic neuronal damage to 
corticosteroid sensitive cells in the hippocampus that are part of the negative 
feedback loop for HPA-axis regulation.  Stress can also cause fat to relocate to 
the visceral fat pad, increasing risk for heart disease and diabetes (Barnes et al., 
1998; Chrousos, 2000a; Chrousos, 2000b).  Finally, excessive exposure to GCs 
is known to lead to metabolic syndrome, and increase risk for cardiovascular 
disease and obesity (Rosmond, 2005).   
MS is also commonly associated with various mood disorders, including 
depression (Arnett, 2005; Brown et al., 2005; Dalton and Heinrichs, 2005; Ehde 
and Bombardier, 2005; Galeazzi et al., 2005; Hart et al., 2005; Heesen et al., 
2005; Iwasaki et al., 2005; Rickards, 2005; Siegert and Abernethy, 2005).  
Depressive symptoms include weight loss, anhedonia (loss of interest in 
pleasurable activities), hyperalgesia and/ or allodynia, decreased activity, and 
alterations in sleep patterns and quality of sleep.  Interestingly, cytokine-
mediated sickness syndrome includes many of these symptoms as well 
(Charlton, 2000; Elenkov et al., 2005).  Depression is also commonly associated 
with elevated pro-inflammatory cytokines (Heesen et al., 2005).  However, one 
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of the most compelling theories of depression is that GCR is the underlying 
cause of depression, through dysregulation of the pro-inflammatory response 
(Caamano et al., 2001; Hill and Gorzalka, 2005; Wang et al., 2005).   
Although IL-6 may contribute to the development of GCR, SDR induced 
GCR is also responsible for the overall increase in pro-inflammatory cytokine (IL-
6) levels, through the deregulation of cytokine production from the macrophages.  
In animals with elevated IL-6 (SDR-VEH), TMEV infection resulted in elevated 
sickness behaviors, including body weight loss, anhedonia, allodynia, and 
reduced activity.  By blocking the activity of IL-6, these effects were also 
blocked.  Those animals with elevated sickness behaviors also had exacerbated 
motoric impairment, impaired viral clearance and excessive inflammation.  
Therefore, SDR induced exacerbations of TMEV infection parallels the effects of 
stress in MS in several ways, including the development of depression and 
motor impairment.  Although the acute phase of TMEV is not generally 
considered the important period in relation to MS, it is CNS inflammatory, 
providing a model for the inflammatory periods in MS and other CNS 
inflammatory diseases. 
In the future, the role of GCR in the development of both depressive 
symptoms and motor impairment in TMEV infection should be examined, 
separate from stress.  By separating stress and GCR, we can increase 
understanding of whether stress directly alters TMEV infection development, 
primarily acts through GCR, or some other pathway.  Currently, in animal 
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models of stress, only social stressors effectively induce GCR, while other types 
(i.e. restraint) fail to do so (Avitsur et al., 2003a; Avitsur et al., 2003b; Avitsur et 
al., 2002; Bailey et al., 2004).  Using other social stress models, or other 
immune activation models would not allow the investigation into the isolated 
effects of GCR in this model.  One other option is available, casein could be 
used to examine the effects of GCR in the absence of stress.  The milk protein, 
casein, induces GCR as well (Carbone et al., 1990; Chen et al., 1998; Dmitrieva 
et al., 1990; Kay et al., 1981; Kehoe and Shoemaker, 1991; Rosene et al., 2004; 
Thibault and Roberge, 1988; Thurmond and Brown, 1984).  Thus, casein 
administration could be used to examine the effects of GCR alone, in the 
absence of social stress, on acute TMEV infection, as well as depression-like 
sickness behaviors.   
While the broader systemic role of GCR is interesting, it would also be 
important for future studies to examine GCR in the CNS inflammatory responses 
detected by the current study.  In the current study, SDR alone was associated 
with significantly greater levels of inflammation, primarily in the hippocampal and 
penduncular regions of the brain.  In contrast, IL-6 treatment was not associated 
with elevation in inflammation, but blocking IL-6 with neutralizing antibodies 
blocked SDR-related inflammation.  Therefore, once again, GCR may be 
important.   
SDR-induced GCR is known to occur in the macrophages in the spleen 
(Avitsur et al., 2002).  Development of GCR directly in the CNS would have 
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important implications.  Inflammation in the CNS is primarily due to the presence 
and action of microglia and macrophages.  In addition, functional GCs are 
essential in protecting CNS tissue during inflammatory responses (Nadeau and 
Rivest, 2003).  Thus, developing an assay that would assess GCR in brain 
and/or spinal tissue and further assessment of what cell types are responsible 
for the GCR would be informative.   
In the current study, GCR was associated with IL-6 elevation.  However, 
as in previous studies, IL-6 was not necessary nor sufficient for the development 
of GCR (Stark et al., 2002).  Thus, it seems plausible that the GCR may 
contribute to the deregulation macrophage production, which in turn may lead to 
the elevation of IL-6.  However, it is also possible that IL-6 may influence GCR 
through other co-factors.  For example, it has been established that elevated 
proinflammatory cytokines are correlated with increased expression of the beta  
subtype of the GC receptor.  Glucocorticoid resistance is also associated with 
elevated levels of the beta  subtype of the GC receptor (Necela and Cidlowski, 
2004). Therefore, it may be possible for elevated IL-6 to increase expression of 
the beta subtype GCR receptor, and this may lead to the development of GCR. 
IL-6 plays an important role in both SDR and acute TMEV infection.  In TMEV 
infection, IL-6 is essential for microglia to become efficient antigen presenting 
cells (Mack et al., 2003). This can have both positive and negative outcomes.  
First, antigen presentation is an essential step in the development of the 
humoral and cellular adaptive immune responses.  If the antigen is not properly 
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presented, then the appropriate cells will not traffic to the area of insult and 
neutralize the pathogen, or lyse the infected cell.  However, TMEV infection 
results in an autoimmune mediated demyelinating process.  One important 
vector for the development of the autoimmune response is through molecular 
mimicry.  This occurs when T-cells and B-cells first develop responses to the 
virus.  Then, if the viral molecular structure is similar to that of myelin, then the 
responses that develop will also attack and kill myelin (Fujinami and Zurbriggen, 
1989).  The portion of the virus that is presented by the antigen-presenting cell is 
an important factor in this development of molecular mimicry.  Without antigen 
presentation, the virus would not be able to cause the development of auto-
reactive T-cells and B-cells.  Without antigen presentation the virus may take 
over the organism and directly kill the host, but antigen presentation may also be 
the cause of later autoimmune reactivity.   
The current data indicated that IL-6 was not sufficient to induce the 
negative effects of SDR.  However, in order to fully examine this issue, 
additional experiments should be considered.  As mentioned previously, a higher 
dose may be needed.  IL-6 may have an essential role that was not accessed by 
the current study.  We have a sub-threshold dose of IL-6 used here.  This dose 
should be combined with a sub-threshold dose of SDR (i.e. fails to develop 
GCR, and/or fails to alter acute TMEV infection).  This experiment would allow a 
more nuanced investigation of the role of IL-6.  Perhaps it is the IL-6 released 
due to the higher levels of SDR that results in the negative effects in acute 
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TMEV infection.  Thus, the effects of SDR and IL-6 may be additive on TMEV 
infection.  
Although the current data and other sources demonstrate that excessive 
IL-6 is associated with the negative outcomes in TMEV infection, IL-6 can also 
have protective effects.  In one recent study, IL-6-/- mice with the appropriate 
MHC haplotype (so the mice were susceptible to TMEV infection), developed 
greater mortality and spinal anterior horn demyelination compared to IL-6+/+ 
mice (Pavelko et al., 2003).  Thus, a complete lack of IL-6 is also damaging to 
neurological tissue.  An additional study has also found central administration of 
human recombinant IL-6 can be protective in TMEV infection (Rodriguez et al., 
1994). 
The current data indicates that fewer microglia are activated when IL-6 is 
blocked.  Therefore, microglia activation may be important in SDR-TMEV 
infection interactions.  While IL-6 may be important in activating and aiding in 
proliferation of microglia and/or trafficking of macrophages, the microglia may 
have independent effects on TMEV infection.  In addition, future studies should 
block microglia activation during SDR.  The drug, minocycline inhibits microglia 
activation and proliferation (Ledeboer et al., 2005; Tikka et al., 2001), and could 
be used to examine the separate effects of SDR, GCR and microglia on TMEV 
infection.  Minocycline could be administered during SDR to block SDR induced 
microglia activity (and probably IL-6, although IL-6 may be sourced from other 
neuronal or astrocytic tissue).  Minocycline could also be administered during 
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infection to examine the specific role of microglia in TMEV separately from SDR.  
Administration of minocycline could also be used in conjunction with casein 
administration to examine GCR related microglia activation in the absence of 
SDR, examining both GCR and microglia activity in acute TMEV infection.  
TMEV up regulates many of the pro-inflammatory cytokines as early as 1 h post 
infection in cell culture including IL-1, IL-6, and TNF-α (Olson et al., 2001; Palma 
et al., 2003).  Microglia cultures became efficient antigen-presenting cells of 
myelin proteins following infection with TMEV, indicating that microglia may be 
important in developing the autoimmune regulated demyelination in the chronic 
phase of TMEV infection (Olson et al., 2001).  In vitro, these cytokines are also 
known to be elevated in sera (Chang et al., 2000).  Thus, blocking microglia 
would block many of the probable mechanisms that exacerbate the infection 
process.   
SDR-induced GCR has one additional mechanism that also needs to be 
elucidated, separate from the effects on acute TMEV infection.  GCR occurs in 
splenic macrophages, not due to a morphological change, but though release of 
more mature macrophages from the bone marrow that then traffic to the spleen 
(Engler et al., 2004).  GCs are unlikely to have this action, in part because GC 
receptors are not common in bone marrow cells.  In addition, previous studies 
from our laboratory used exogenous corticosteroids, and mimicked restraint 
stress, and restraint stress does not induce GCR (Avitsur et al., 2001; Satterlee 
et al., 2001).   Norepinephrine is a more likely candidate, as there is direct 
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sympathetic innervation of the bone marrow (Felten et al., 1998).  
Norepinephrine (NE) blockade through drugs such as nadalol would be a good 
first step to examine the necessity of NE.  Another option would be to 
sympathectomize the mice with 6-ODHA.  This procedure has many other 
negative side effects, including that the mice become very delicate, making 
subsequent exposure to SDR difficult.  Because these mice are usually sickly, 
the dominant is unlikely to attack them, and if the dominant does attack, the 
mice are more likely to die.  With these limitations, osmotic pumps or pellet 
implants of nadalol or other similar drugs would be the most likely to result in 
interpretable data.   
The role of stress is also important to consider, separate from the 
physiological pathways discussed.   For instance, in studies from other 
laboratories, wounding is required in SDR for the development of GCR (Avitsur 
et al., 2005; Avitsur et al., 2003a; Avitsur et al., 2003b; Avitsur et al., 2002; 
Avitsur et al., 2001; Stark et al., 2002; Stark et al., 2001).  The studies from other 
laboratories all use the mouse strain, C57BL/6J, whereas the current study used 
Balb/cJ.  C57BL/6J mice are not susceptible to TMEV infection.  Having the 
genetic haplotype(s) for susceptibility is required for the development of both 
TMEV infection in mice (Oleszak et al., 2004), and MS in humans (Sospedra 
and Martin, 2005).  Thus, in order to examine the role of SDR in TMEV infection, 
only susceptible strains of mice, such as the Balb/cJ strain, can be used.  The 
Balb/cJ mice developed  
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biological perspectives (Cohen et al., 1995). 
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GCR in the absence of wounding.  Therefore, the Balb/cJ mice differ from the 
C57BL/6J mice in ways other than having TMEV susceptibility.  One study has 
shown that Balb/cJ mice are more stress hyper-responsive than the C57BL/6J 
mice (Shanks et al., 1990).  In contrast, the C57BL/6J mice may require more 
antagonistic interactions, resulting in wounding in order for GCR to develop 
compared to the Balb/cJ strain.   
 C57BL/6J mice may not assess threat unless wounding occurs.  In 
contrast, Balb/cJ mice may perceive the dominant’s presence, and/or attacks as 
being more threatening than the C57BL/6J mice (without wounding).  This 
explanation fits nicely with Cohen’s model of stress response (Fig 5.2.).  
Cohen’s model includes an important role for threat assessment.  Once a 
potential environmental demand occurs, the organism then appraises the 
demand as well as the organism’s coping skill, resulting in either a benign or 
threatening assessment (Cohen et al., 1995). Some evidence to support this 
theory has previously been documented, showing that under similar basal or 
stress conditions, Balb/cJ mice have greater corticosteroid responses compared 
to C57BL/6J mice (Shanks et al., 1990; Tang et al., 2002).  
The stress-responsivity may effect both the development of GCR, as well 
as have direct effects on disease development.  One possible way to examine 
this issue physiologically would be to administer anti-anxiolytics, in order to 
reduce the Balb/cJ stress response.  By altering the stress response, this 
treatment may alter either the development of GCR, the release of IL-6, or more 
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directly the development of TMEV infection.  In humans (e.g. in MS patients) 
both psychotropic drugs, such as anti-anxiolytics, could be used, but also less 
invasive options such as cognitive-behavioral stress management.   
 Cognitive behavioral stress management has been shown to help 
maintain T-cell counts and improve quality of life in AIDS patients (Antoni et al., 
1991).  MS is also mediated through auto-reactive CD4+ T-cells (Sospedra and 
Martin, 2005).  While increasing CD4+ cells or function in MS would be counter-
productive, cognitive behavioral therapy may still be helpful to improve quality of 
life.  As previously noted, depressive symptoms common to MS are likely to 
improve with such interventions. 
 The current study demonstrated the necessity, but not sufficiency, of IL-6 
in mediating the effects of SDR in exacerbating acute TMEV infection.  These 
findings implicate several other important physiological pathways in the 
development of TMEV infection that are also relevant to MS.  This study also 
further demonstrates the importance of the TMEV model in investigating the  
effects of social stress in MS.  By pursuing the pathways implicated in the 
current study, a great deal of understanding of stress and MS would result.  
Finally, further elucidation of SDR on acute TMEV may also aid in understanding 
other CNS inflammatory neurodegenerative disorders (Alzheimer’s disease, 
Parkinson’s disease, AIDS) as well as depression.  Thus, SDR-TMEV infection 
interaction studies will continue to benefit a broad range of public health issues.   
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6. CONCLUSION 
The current study examined the role of IL-6 in the negative effects of SDR 
on acute TMEV infection.  Past work had shown that SDR applied prior to 
infection exacerbated disease course in both the acute and chronic phase of 
TMEV infection.  The working hypothesis was that IL-6 would be necessary, but 
not sufficient, in mediating the effects of SDR on acute TMEV infection.  In order 
to examine the development of the disease, a battery of illness, motor 
impairment, and physiological measures were collected. 
The objective of Experiment 1 was to examine the necessity of IL-6 in the 
effects of SDR in the acute phase of TMEV infection. IL-6 was blocked with a 
neutralizing polyclonal antibody against murine IL-6.  When IL-6 was blocked, 
the exacerbating effects of SDR were reversed in the illness, motor impairment 
and physiological measures.  These data indicated that IL-6 was in fact 
necessary, confirming our original hypothesis. 
The objective of Experiment 2 was to examine the sufficiency of IL-6 in 
mimicking the effects of SDR in acute TMEV infection.  SDR was replaced with a 
dose of recombinant murine IL-6 that was similar to that found in SDR animals in 
the current study, as well as others (Stark et al., 2002).  IL-6 alone induced 
hypothermia and increased mechanical sensitivity in the first 24-h of infection, 
indicating that this dose of IL-6 was sufficient to induce some illness effects, 
somewhat similar to SDR.  However, IL-6 was not sufficient to induce the 
remainder of illness effects.  In addition, this dose of IL-6 was not sufficient to 
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replicate SDR effects on motor impairment or physiological measures.  These 
data also confirm the original hypothesis that IL-6 alone is not sufficient to mimic 
the effects of SDR.  However, this conclusion should not be considered 
concrete, as a higher dose of IL-6 may be more effective. 
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